STRYKER CORP, 10-K filed on 2/12/2025
Annual Report
v3.25.0.1
COVER PAGE - USD ($)
 12 Months Ended
Dec. 31, 2024
Jan. 31, 2025
Jun. 30, 2024
Entity Information [Line Items]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2024    
Current Fiscal Year End Date --12-31    
Document Transition Report false    
Entity File Number 001-13149    
Entity Registrant Name STRYKER CORP    
Entity Incorporation, State or Country Code MI    
Entity Tax Identification Number 38-1239739    
Entity Address, Address Line One 1941 Stryker Way,    
Entity Address, City or Town Portage,    
Entity Address, State or Province MI    
Entity Address, Postal Zip Code 49002    
City Area Code (269)    
Local Phone Number 385-2600    
Title of 12(g) Security None    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Entity Emerging Growth Company false    
Entity Small Business false    
ICFR Auditor Attestation Flag true    
Document Financial Statement Error Correction [Flag] false    
Entity Shell Company false    
Entity Public Float     $ 123,147,898,554
Entity Common Stock, Shares Outstanding   381,579,123  
Documents Incorporated by Reference
Portions of the proxy statement to be filed with the U.S. Securities and Exchange Commission relating to the 2025 Annual Meeting of Shareholders (the 2025 proxy statement) are incorporated by reference into Part III.
    
Amendment Flag false    
Document Fiscal Year Focus 2024    
Document Fiscal Period Focus FY    
Entity Central Index Key 0000310764    
Common Stock, $.10 Par Value      
Entity Information [Line Items]      
Title of 12(b) Security Common Stock, $.10 Par Value    
Trading Symbol SYK    
Security Exchange Name NYSE    
2.125% Notes due 2027      
Entity Information [Line Items]      
Title of 12(b) Security 2.125% Notes due 2027    
Trading Symbol SYK27    
Security Exchange Name NYSE    
3.375% Notes due 2028      
Entity Information [Line Items]      
Title of 12(b) Security 3.375% Notes due 2028    
Trading Symbol SYK28    
Security Exchange Name NYSE    
0.750% Notes due 2029      
Entity Information [Line Items]      
Title of 12(b) Security 0.750% Notes due 2029    
Trading Symbol SYK29    
Security Exchange Name NYSE    
2.625% Notes due 2030      
Entity Information [Line Items]      
Title of 12(b) Security 2.625% Notes due 2030    
Trading Symbol SYK30    
Security Exchange Name NYSE    
1.000% Notes due 2031      
Entity Information [Line Items]      
Title of 12(b) Security 1.000% Notes due 2031    
Trading Symbol SYK31    
Security Exchange Name NYSE    
3.375% Notes due 2032      
Entity Information [Line Items]      
Title of 12(b) Security 3.375% Notes due 2032    
Trading Symbol SYK32    
Security Exchange Name NYSE    
3.625% Notes due 2036      
Entity Information [Line Items]      
Title of 12(b) Security 3.625% Notes due 2036    
Trading Symbol SYK36    
Security Exchange Name NYSE    
v3.25.0.1
Audit Information
 12 Months Ended
Dec. 31, 2024
Auditor Information [Abstract]  
Auditor Firm ID 42
Auditor Name Ernst & Young LLP
Auditor Location Grand Rapids, Michigan
v3.25.0.1
Consolidated Statements Of Earnings - USD ($)
shares in Millions, $ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Income Statement [Abstract]      
Net sales $ 22,595 $ 20,498 $ 18,449
Cost of sales 8,155 7,440 6,871
Gross profit 14,440 13,058 11,578
Research, development and engineering expenses 1,466 1,388 1,454
Selling, general and administrative expenses 7,685 7,111 6,386
Amortization of intangible assets 623 635 627
Goodwill and other impairments 977 36 270
Total operating expenses 10,751 9,170 8,737
Operating income 3,689 3,888 2,841
Other income (expense), net (197) (215) (158)
Earnings before income taxes 3,492 3,673 2,683
Income taxes 499 508 325
Net earnings $ 2,993 $ 3,165 $ 2,358
Net earnings per share of common stock:      
Basic net earnings per share of common stock (in dollars per share) $ 7.86 $ 8.34 $ 6.23
Diluted net earnings per share of common stock (in dollars per share) $ 7.76 $ 8.25 $ 6.17
Weighted-average shares outstanding (in millions):      
Basic (in shares) 381.0 379.6 378.2
Effect of dilutive employee stock compensation (in shares) 4.6 4.1 4.0
Diluted (in shares) 385.6 383.7 382.2
v3.25.0.1
Consolidated Statements Of Earnings (Parenthetical) - shares
shares in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Income Statement [Abstract]      
Anti-dilutive shares excluded from calculation of dilutive employee stock options (in shares) 0.0 4.3 0.0
v3.25.0.1
Consolidated Statements of Comprehensive Income - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Statement of Comprehensive Income [Abstract]      
Net earnings $ 2,993 $ 3,165 $ 2,358
Other comprehensive income (loss), net of tax      
Marketable securities 0 1 (1)
Pension plans 32 (59) 186
Unrealized gains (losses) on designated hedges (8) (13) 12
Financial statement translation 99 (124) 113
Total other comprehensive income (loss), net of tax 123 (195) 310
Comprehensive income $ 3,116 $ 2,970 $ 2,668
v3.25.0.1
Consolidated Balance Sheets - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Current assets    
Cash and cash equivalents $ 3,652 $ 2,971
Short-term investments 750 0
Marketable securities 91 82
Accounts receivable, less allowance of $213 ($182 in 2023) 3,987 3,765
Inventories:    
Materials and supplies 1,147 1,242
Work in process 336 330
Finished goods 3,291 3,271
Total inventories 4,774 4,843
Prepaid expenses and other current assets 1,593 857
Total current assets 14,847 12,518
Property, plant and equipment:    
Land, buildings and improvements 1,627 1,692
Machinery and equipment 5,056 4,652
Total property, plant and equipment 6,683 6,344
Less allowance for depreciation 3,235 3,129
Property, plant and equipment, net 3,448 3,215
Goodwill 15,855 15,243
Other intangibles, net 4,395 4,593
Noncurrent deferred income tax assets 1,742 1,670
Other noncurrent assets 2,684 2,673
Total assets 42,971 39,912
Current liabilities    
Accounts payable 1,679 1,517
Accrued compensation 1,403 1,478
Income taxes 539 391
Dividend payable 320 304
Accrued expenses and other liabilities 2,266 2,137
Current maturities of debt 1,409 2,094
Total current liabilities 7,616 7,921
Long-term debt, excluding current maturities 12,188 10,901
Income taxes 349 567
Other noncurrent liabilities 2,184 1,930
Total liabilities 22,337 21,319
Shareholders' equity    
Common stock, $0.10 par value 38 38
Additional paid-in capital 2,361 2,200
Retained earnings 18,528 16,771
Accumulated other comprehensive loss (293) (416)
Total shareholders' equity 20,634 18,593
Total liabilities & shareholders' equity $ 42,971 $ 39,912
Common stock, par value (in dollars per share) $ 0.10 $ 0.10
v3.25.0.1
Consolidated Balance Sheets (Parentheticals) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Statement of Financial Position [Abstract]    
Accounts receivable, allowance $ 213 $ 182
Common stock, par value (in dollars per share) $ 0.10 $ 0.10
v3.25.0.1
Consolidated Statements Of Shareholders' Equity - USD ($)
shares in Millions, $ in Millions
Total
Common Stock
Additional Paid-In Capital
Retained Earnings
Accumulated Other Comprehensive Income (Loss)
Beginning balance at Dec. 31, 2021   $ 38 $ 1,890 $ 13,480 $ (531)
Beginning balance, shares at Dec. 31, 2021   377.5      
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock under stock compensation and benefit plans   $ 0 (24)    
Issuance of common stock under stock compensation and benefit plans, shares   1.2      
Share-based compensation     168    
Net earnings $ 2,358     2,358  
Cash dividends declared       (1,073)  
Other comprehensive income (loss) 310       310
Ending balance, shares at Dec. 31, 2022   378.7      
Ending balance at Dec. 31, 2022 16,616 $ 38 2,034 14,765 (221)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock under stock compensation and benefit plans   $ 0 (39)    
Issuance of common stock under stock compensation and benefit plans, shares   1.4      
Share-based compensation     205    
Net earnings 3,165     3,165  
Cash dividends declared       (1,159)  
Other comprehensive income (loss) (195)       (195)
Ending balance, shares at Dec. 31, 2023   380.1      
Ending balance at Dec. 31, 2023 18,593 $ 38 2,200 16,771 (416)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock under stock compensation and benefit plans   $ 0 (68)    
Issuance of common stock under stock compensation and benefit plans, shares   1.3      
Share-based compensation     229    
Net earnings 2,993     2,993  
Cash dividends declared       (1,236)  
Other comprehensive income (loss) 123        
Ending balance, shares at Dec. 31, 2024   381.4      
Ending balance at Dec. 31, 2024 $ 20,634 $ 38 $ 2,361 $ 18,528 $ (293)
v3.25.0.1
Consolidated Statements Of Cash Flows - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Operating activities      
Net earnings $ 2,993 $ 3,165 $ 2,358
Adjustments to reconcile net earnings to net cash provided by operating activities:      
Depreciation 427 393 371
Amortization of intangible assets 623 635 627
Goodwill and other impairments 977 36 270
Share-based compensation 229 205 168
Sale of inventory stepped up to fair value at acquisition 46 0 12
Deferred income tax (benefit) expense (370) (206) 58
Changes in operating assets and liabilities:      
Accounts receivable (321) (175) (579)
Inventories (206) (797) (762)
Accounts payable 192 77 290
Accrued expenses and other liabilities 74 516 156
Income taxes (116) (4) (238)
Other, net (306) (134) (107)
Net cash provided by operating activities 4,242 3,711 2,624
Investing activities      
Acquisitions, net of cash acquired (1,628) (390) (2,563)
Purchase of short-term investments (750) 0 0
Purchases of marketable securities (58) (52) (52)
Proceeds from sales of marketable securities 49 54 43
Purchases of property, plant and equipment (755) (575) (588)
Proceeds from settlement of net investment hedges 99 0 197
Other investing, net 43 1 39
Net cash used in investing activities (3,000) (962) (2,924)
Financing activities      
Proceeds (payments) on short-term borrowings, net (32) 540 (375)
Proceeds from issuance of long-term debt 3,011 1,241 1,500
Payments on long-term debt (2,039) (2,058) (653)
Payments of dividends (1,219) (1,139) (1,051)
Cash paid for taxes from withheld shares (195) (155) (122)
Other financing, net (51) (23) (48)
Net cash provided by (used in) financing activities (525) (1,594) (749)
Effect of exchange rate changes on cash and cash equivalents (36) (28) (51)
Change in cash and cash equivalents 681 1,127 (1,100)
Cash and cash equivalents at beginning of year 2,971 1,844 2,944
Cash and cash equivalents at end of year 3,652 2,971 1,844
Supplemental cash flow disclosure:      
Cash paid for income taxes, net of refunds 989 693 505
Cash paid for interest on debt $ 396 $ 356 $ 324
v3.25.0.1
Significant Accounting Policies
 12 Months Ended
Dec. 31, 2024
Accounting Policies [Abstract]  
Significant Accounting Policies SIGNIFICANT ACCOUNTING POLICIES
Nature of Operations: Stryker (the "Company," "we," "us," or "our") is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Our products include surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling, emergency medical equipment and intensive care disposable products; clinical communication and artificial intelligence-assisted virtual care platform technology; neurosurgical and neurovascular devices; implants used in joint replacement and trauma surgeries; Mako Robotic-Arm Assisted technology; spinal devices; as well as other products used in a variety of medical specialties.
During the fourth quarter 2024 we changed the name of our “Orthopaedics and Spine” operating segment to “Orthopaedics.”
Basis of Presentation and Consolidation: The Consolidated Financial Statements include the Company and its subsidiaries. All significant intercompany accounts and transactions are eliminated in consolidation. We have no material interests in variable interest entities. Certain prior year amounts have been reclassified to conform with current year presentation in our Consolidated Financial Statements.
Our reportable segments and related disclosures reflect certain reclassifications of prior year amounts from our Orthopaedics segment to our MedSurg and Neurotechnology segment due to changes in our internal reporting structure.
Use of Estimates: The preparation of financial statements in conformity with accounting principles generally accepted in the United States (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities on the date of the financial statements and the reported amounts of net sales and expenses in the reporting period. Actual results could differ from those estimates.
Revenue Recognition: Sales are recognized as the performance obligations to deliver products or services (including services under extended warranty service contracts) are satisfied and are recorded based on the amount of consideration we expect to receive in exchange for satisfying the performance obligations. Our sales are recognized primarily when we transfer control to the customer, which can be on the date of shipment, the date of receipt by the customer or, for most Orthopaedics products, when we have received a purchase order and appropriate notification the product has been used or implanted. Products and services are primarily transferred to customers at a point in time, with some transfers of services taking place over time.
Sales represent the amount of consideration we expect to receive from customers in exchange for transferring products and services. Net sales exclude sales, value added and other taxes we collect from customers. Other costs to obtain and fulfill contracts are generally expensed as incurred due to the short-term nature of most of our sales. We extend terms of payment to our customers based on commercially reasonable terms for the markets of our customers, while also considering their credit quality.
A provision for estimated sales returns, discounts and rebates is recognized as a reduction of sales in the same period that the sales are recognized. Our estimate of the provision for sales
returns has been established based on contract terms with our customers and historical business practices and current trends. Shipping and handling costs charged to customers are included in net sales.
Cost of Sales: Cost of sales include direct materials and supplies consumed in the manufacture of product, as well as manufacturing labor, depreciation expense and direct overhead expense necessary to acquire and convert the purchased materials and supplies into finished product. Cost of sales also includes the cost to distribute products to customers, inbound freight costs, warehousing costs and other shipping and handling activity.
Research, Development and Engineering Expenses: Research, development and engineering costs are charged to expense as incurred and include research, development and engineering activities relating to the development of new products, improvement of existing products, technical support of products and compliance with governmental regulations for the protection of customers and patients. Costs primarily include salaries, wages, consulting and depreciation and maintenance of research facilities and equipment.
Selling, General and Administrative Expenses: Costs include selling expenses, marketing expenses, administrative and other indirect overhead costs, amortization of loaner instrumentation, depreciation and amortization expense of non-manufacturing assets and other miscellaneous operating items.
Currency Translation: Financial statements of subsidiaries outside the United States generally are measured using the local currency as the functional currency. Adjustments to translate those statements into United States Dollars are recorded in other comprehensive income (OCI). Transactional exchange gains and losses are included in other income (expense), net.
Cash Equivalents: Highly liquid investments with remaining stated maturities of three months or less when purchased or other money market instruments that are redeemable upon demand are considered cash equivalents and recorded at cost.
Short-term Investments: Short-term investments that have a maturity greater than three months and less than a year from the date of purchase primarily include time deposits, certificates of deposit, commercial paper, bonds and notes, substantially all of which are denominated in United States Dollars and are stated at cost plus accrued interest, which approximates fair value. We expect to hold all of our short-term investments to maturity.
Marketable Securities: Marketable securities include marketable debt securities and mutual funds. Mutual funds are acquired to offset changes in certain liabilities related to deferred compensation arrangements and are expected to be used to settle these liabilities and are recognized in other noncurrent assets. Pursuant to our investment policy, all individual marketable security investments must have a minimum credit quality of single A (Standard & Poor’s and Fitch) and A2 (Moody’s Corporation) at the time of acquisition, while the overall portfolio of marketable securities must maintain a minimum average credit quality of double A (Standard & Poor’s and Fitch) or Aa (Moody’s Corporation). In the event of a rating downgrade below the minimum credit quality subsequent to purchase, the marketable security investment is evaluated to determine the appropriate action to take to minimize the overall risk to our marketable security investment portfolio. Our marketable securities are classified as available-for-sale and trading securities. Investments in trading securities represent participant-directed investments of deferred employee compensation.
Accounts Receivable: Accounts receivable include trade and other miscellaneous receivables. An allowance is maintained for doubtful accounts for estimated losses in the collection of accounts receivable. Estimates are made regarding the ability of customers to make required payments based on historical credit experience, current market conditions and expected credit losses. Accounts receivable are written off when all reasonable collection efforts are exhausted.
Inventories: Inventories are stated at the lower of cost or net realizable value, with cost generally determined using the first-in, first-out (FIFO) cost method. For excess and obsolete inventory resulting from the potential inability to sell specific products at prices in excess of current carrying costs, reserves are maintained to reduce current carrying cost to net realizable value.
Financial Instruments: Our financial instruments include cash, cash equivalents, marketable securities, accounts receivable, other investments, accounts payable, debt and foreign currency exchange contracts. The carrying value of our financial instruments, with the exception of our senior unsecured notes, approximates fair value on December 31, 2024 and 2023. Refer to Notes 3 and 10 for further details.
All marketable securities are recognized at fair value. Adjustments to the fair value of marketable securities that are classified as available-for-sale are recognized as increases or decreases, net of income taxes, within accumulated other comprehensive income (AOCI) in shareholders’ equity and adjustments to the fair value of marketable securities that are classified as trading are recognized in earnings. The amortized cost of marketable debt securities is adjusted for amortization of premiums and discounts to maturity computed under the effective interest method. Such amortization and interest and realized gains and losses are included in other income (expense), net. The cost of securities sold is determined by the specific identification method.
We review declines in the fair value of our investments classified as available-for-sale to determine whether the decline in fair value is a result of credit loss or other factors. Impairments of available-for-sale marketable debt securities related to credit loss are included in earnings and impairments related to other factors are recognized within AOCI.
Derivatives: All derivatives are recognized at fair value and reported on a gross basis. We enter into forward currency exchange contracts to mitigate the impact of currency fluctuations on transactions denominated in nonfunctional currencies, thereby limiting our risk that would otherwise result from changes in exchange rates. The periods of the forward currency exchange contracts correspond to the periods of the exposed transactions, with realized gains and losses included in the measurement and recording of transactions denominated in the nonfunctional currencies. All forward currency exchange contracts are recorded at their fair value each period.
Forward currency exchange contracts designated as cash flow hedges are designed to hedge the variability of cash flows associated with forecasted transactions denominated in a foreign currency that will take place in the future. These nonfunctional currency exposures principally relate to forecasted intercompany sales and purchases of manufactured products and generally have maturities up to eighteen months. Changes in value of derivatives designated as cash flow hedges are recorded in AOCI on the Consolidated Balance Sheets until earnings are affected by the variability of the underlying cash flows. At that time, the applicable amount of gain or loss from the derivative instrument that is deferred in shareholders’ equity is reclassified into
earnings and is included in cost of goods sold. Cash flows associated with these hedges are included in cash provided by operating activities in the same category as the cash flows from the items being hedged.
Forward currency exchange contracts are used to offset our exposure to the change in value of specific foreign currency denominated assets and liabilities, primarily intercompany payables and receivables. These derivatives are not designated as hedges and, therefore, changes in the value of these forward contracts are recognized in earnings, thereby offsetting the current earnings effect of the related changes in value of foreign currency denominated assets and liabilities. The estimated fair value of our forward currency exchange contracts represents the measurement of the contracts at month-end spot rates as adjusted by current forward points.
From time to time, we designate derivative and non-derivative financial instruments as net investment hedges of our investments in certain international subsidiaries. For derivative instruments that are designated and qualify as a net investment hedge, the effective portion of the derivative's gain or loss is recognized in OCI and reported as a component of AOCI. We have elected to use the spot method to assess effectiveness for our derivatives designated as net investment hedges. Accordingly, the change in fair value attributable to changes in the spot rate is recorded in AOCI. We exclude the spot-forward difference from the assessment of hedge effectiveness and amortize this amount separately on a straight-line basis over the term of the forward contracts. This amortization is recognized in other income (expense), net.
From time to time, we designate forward starting interest rate derivative instruments as cash flow hedges to manage the exposure to interest rate volatility with regard to future issuance and refinancing of debt. Changes in value of derivatives designated as cash flow hedges are recorded in AOCI until earnings are affected by the variability of the underlying cash flows. At that time, the applicable amount of gain or loss from the derivative instrument that is deferred in shareholders’ equity is reclassified into earnings and is included in interest expense within other income (expense), net.
Interest rate derivative instruments designated as fair value hedges have been used in the past to manage the exposure to interest rate movements and to reduce borrowing costs by converting fixed-rate debt into floating-rate debt. Under these agreements, we agree to exchange, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount.
Property, Plant and Equipment: Property, plant and equipment is stated at cost. Depreciation is generally computed by the straight-line method over the estimated useful lives of three to 30 years for buildings and improvements and three to 15 years for machinery and equipment.
Goodwill and Other Intangible Assets: Goodwill represents the excess of purchase price over fair value of tangible net assets of acquired businesses at the acquisition date, after amounts allocated to other identifiable intangible assets. Factors that contribute to the recognition of goodwill include synergies that are specific to our business and not available to other market participants and are expected to increase net sales and profits; acquisition of a talented workforce; cost savings opportunities; the strategic benefit of expanding our presence in core and adjacent markets; and diversifying our product portfolio.
The fair values of other identifiable intangible assets acquired in a business combination are primarily determined using the income
approach. Other intangible assets include, but are not limited to, developed technology, customer and distributor relationships (which reflect expected continued customer or distributor patronage) and trademarks and patents. Intangible assets with determinable useful lives are amortized on a straight-line basis over their estimated useful lives of four to 40 years. Certain acquired trade names are considered to have indefinite lives and are not amortized, but are assessed annually for potential impairment as described below.
In some of our acquisitions, we acquire in-process research and development (IPRD) intangible assets. For acquisitions accounted for as business combinations IPRD is considered to be an indefinite-lived intangible asset until the research is completed (then it becomes a determinable-lived intangible asset) or determined to have no future use (then it is impaired). For asset acquisitions IPRD is expensed immediately unless there is an alternative future use.
Goodwill, Intangibles and Long-Lived Asset Impairment Tests: We perform our annual impairment test for goodwill as of October 31 each year. We consider qualitative indicators of the fair value of a reporting unit when it is unlikely that a reporting unit has impaired goodwill and periodically corroborate that assessment with quantitative information. In certain circumstances, we may also utilize a discounted cash flow analysis that requires certain assumptions and estimates be made regarding market conditions and our future profitability. Indefinite-lived intangible assets are also tested at least annually for impairment by comparing the individual carrying values to the fair value.
We review long-lived assets for indicators of impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. The evaluation is performed at the lowest level of identifiable cash flows. Undiscounted cash flows expected to be generated by the related assets are estimated over the asset's useful life based on updated projections. If the evaluation indicates that the carrying amount of the asset may not be recoverable, any potential impairment is measured based upon the fair value of the related asset or asset group as determined by an appropriate market appraisal or other valuation technique.
Assets and Liabilities Held for Sale: We classify assets and liabilities or disposal groups to be sold as held for sale in the period in which all of the following criteria are met: management, having the authority to approve the action, commits to a plan to sell the disposal group; the disposal group is available for immediate sale in its present condition subject only to terms that are usual and customary for sales of such disposal groups; an active program to locate a buyer and other actions required to complete the plan to sell the disposal group have been initiated; the sale of the disposal group is probable, and transfer of the disposal group is expected to qualify for recognition as a completed sale within one year, except if events or circumstances beyond our control extend the period of time required to sell the disposal group beyond one year; the disposal group is being actively marketed for sale at a price that is reasonable in relation to its current fair value; and actions required to complete the plan indicate that it is unlikely that significant changes to the plan will be made or that the plan will be withdrawn.
We initially measure a disposal group that is classified as held for sale at the lower of its carrying value or fair value less any costs to sell. Any loss resulting from this measurement is recognized in the period in which the held for sale criteria are met. Conversely, gains are not recognized on the sale of a disposal group until the sale is completed. We assess the fair value of a disposal group, less any costs to sell, each reporting period it remains classified as held for sale and report any subsequent changes as an adjustment to the carrying value of the disposal group, as long as the new carrying value does not exceed the carrying value of the disposal group at the time it was initially classified as held for sale.
Upon determining that a disposal group meets the criteria to be classified as held for sale, we cease depreciation and amortization of the assets and disclose the major classes of assets and liabilities of the disposal group in the Notes to the Consolidated Financial Statements. Refer to Note 16 for further information.
Share-Based Compensation: Share-based compensation is in the form of stock options, restricted stock units (RSUs) and performance stock units (PSUs). Stock options are granted under long-term incentive plans to certain key employees and non-employee directors at an exercise price not less than the fair market value of the underlying common stock, which is the quoted closing price of our common stock on the day prior to the date of grant. The options are granted for periods of up to 10 years and become exercisable in varying installments.
We grant RSUs to key employees and non-employee directors and PSUs to certain key employees under our long-term incentive plans. The fair value of RSUs is determined based on the number of shares granted and the quoted closing price of our common stock on the date of grant, adjusted for the fact that RSUs do not include anticipated dividends. RSUs generally vest in one-third increments over a three-year period and are settled in stock. PSUs are earned over a three-year performance cycle and vest in March of the year following the end of that performance cycle. The number of PSUs that will ultimately be earned is based on our performance relative to pre-established goals in that three-year performance cycle. The fair value of PSUs is determined based on the quoted closing price of our common stock on the day of grant.
Compensation expense is recognized in the Consolidated Statements of Earnings based on the estimated fair value of the awards on the grant date. Compensation expense recognized reflects an estimate of the number of awards expected to vest after taking into consideration an estimate of award forfeitures based on actual experience and is recognized on a straight-line basis over the requisite service period, which is generally the period required to obtain full vesting. Management expectations related to the achievement of performance goals associated with PSU grants is assessed regularly and that assessment is used to determine whether PSU grants are expected to vest. If performance-based milestones related to PSU grants are not met or not expected to be met, any compensation expense recognized associated with such grants will be reversed.
Income Taxes: Deferred income tax assets and liabilities are determined based on differences between financial reporting and income tax bases of assets and liabilities and are measured using the enacted income tax rates in effect for the years in which the differences are expected to reverse. Deferred income tax benefits generally represent the change in net deferred income tax assets and liabilities in the year. Other amounts result from
adjustments related to acquisitions and foreign currency as appropriate.
We operate in multiple income tax jurisdictions both within the United States and internationally. Accordingly, management must determine the appropriate allocation of income to each of these jurisdictions based on current interpretations of complex income tax regulations. Income tax authorities in these jurisdictions regularly perform audits of our income tax filings. Income tax audits associated with the allocation of this income and other complex issues, including inventory transfer pricing and cost sharing, product royalty and foreign branch arrangements, may require an extended period of time to resolve and may result in significant income tax adjustments if changes to the income allocation are required between jurisdictions with different income tax rates.
The Tax Cuts and Jobs Act (the Act) was enacted in 2017 in the United States. The Act also subjects a United States shareholder to tax on Global Intangible Low-Taxed Income (GILTI) earned by certain foreign subsidiaries. We have elected to account for GILTI tax in the year the tax is incurred.
New Accounting Pronouncements Not Yet Adopted
In November 2024 the Financial Accounting Standards Board (FASB) issued ASU 2024-03 (Subtopic 220-40): Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures which requires disaggregation of certain expense captions into specified categories in disclosures within the Notes to the Consolidated Financial Statements. The new disclosure requirements are effective for fiscal years beginning after December 15, 2026 and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. We are currently evaluating these new expanded disclosure requirements.
In December 2023 the FASB issued ASU 2023-09 (Topic 740): Income Taxes: Improvements to Income Tax Disclosures which expands the existing rules on income tax disclosures. This update requires entities to disclose specific categories in the tax rate reconciliation, provide additional information for reconciling items that meet a quantitative threshold and disclose additional information about income taxes paid on an annual basis. The new disclosure requirements are effective for fiscal years beginning after December 15, 2024. Early adoption is permitted. We are currently evaluating these new expanded disclosure requirements.
Accounting Pronouncements Recently Adopted
On January 1, 2024 we adopted ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. Refer to Note 14 for further information.
On January 1, 2023 we adopted ASU 2022-04, Liabilities - Supplier Finance Programs: Disclosure of Supplier Finance Program Obligations. Refer to Note 7 for required disclosures.
v3.25.0.1
Revenue Recognition
 12 Months Ended
Dec. 31, 2024
Revenue Recognition [Abstract]  
Revenue Recognition REVENUE RECOGNITION
We disaggregate our net sales by business and geographic location for each of our segments as we believe it best depicts how the nature, amount, timing and certainty of our net sales and cash flows are affected by economic factors.
Products and services are primarily transferred to customers at a point in time, with some transfers of services taking place over time. In 2024 less than 10% of our sales were recognized as services transferred over time. Refer to Note 1 for further discussion on our revenue recognition policies.
In the fourth quarter 2024 we reorganized our Spine business to align with certain updates to our internal reporting structure. The spine enabling technologies portfolio (Enabling Technologies) was reclassified to Other Orthopaedics and Spine, the interventional spine portfolio was reclassified to Neuro Cranial and the remaining Spine business was renamed to Spinal Implants. In addition, we changed the name of our “Orthopaedics and Spine” operating segment to “Orthopaedics.” Neuro Cranial includes sales related to interventional spine of $413, $327 and $282 for 2024, 2023 and 2022. Other Orthopaedics includes sales related to Enabling Technologies of $152, $149 and $131 for 2024, 2023 and 2022. In the first quarter of 2024 a product line previously included in Instruments has been reclassified to Endoscopy to align with a change in our internal reporting structure. We have reflected these changes in all historical periods presented.
Segment Net Sales
MedSurg and Neurotechnology:202420232022
Instruments$2,834 $2,534 $2,245 
Endoscopy3,389 3,068 2,759 
Medical3,852 3,459 3,031 
Neurovascular1,307 1,226 1,200 
Neuro Cranial2,136 1,876 1,658 
$13,518 $12,163 $10,893 
Orthopaedics:
Knees$2,447 $2,273 $1,997 
Hips1,704 1,544 1,413 
Trauma and Extremities3,507 3,147 2,807 
Spinal Implants707 713 733 
Other712 658 606 
$9,077 $8,335 $7,556 
Total$22,595 $20,498 $18,449 
United States Net Sales
MedSurg and Neurotechnology:202420232022
Instruments$2,267 $2,016 $1,776 
Endoscopy2,792 2,513 2,245 
Medical3,191 2,785 2,422 
Neurovascular506 483 446 
Neuro Cranial1,761 1,531 1,359 
$10,517 $9,328 $8,248 
Orthopaedics:
Knees$1,788 $1,676 $1,493 
Hips1,059 988 896 
Trauma and Extremities2,586 2,297 2,035 
Spinal Implants489 500 511 
Other504 468 455 
$6,426 $5,929 $5,390 
Total$16,943 $15,257 $13,638 
International Net Sales
MedSurg and Neurotechnology:202420232022
Instruments$567 $518 $469 
Endoscopy597 555 514 
Medical661 674 609 
Neurovascular801 743 754 
Neuro Cranial375 345 299 
$3,001 $2,835 $2,645 
Orthopaedics:
Knees$659 $597 $504 
Hips645 556 517 
Trauma and Extremities921 850 772 
Spinal Implants218 213 222 
Other208 190 151 
$2,651 $2,406 $2,166 
Total$5,652 $5,241 $4,811 
MedSurg and Neurotechnology
MedSurg and Neurotechnology products include surgical equipment, patient and caregiver safety technologies (Instruments), endoscopic and communications systems (Endoscopy), and patient handling, emergency medical equipment, intensive care disposable products and clinical communication and artificial intelligence-assisted virtual care platform technology (Medical), minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke (Neurovascular), cranial, maxillofacial and chest wall devices as well as dural substitutes and sealants; a comprehensive line of products for traditional brain and open skull based surgical procedures; orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products (Neuro Cranial). Substantially all MedSurg and Neurotechnology sales are recognized when a purchase order has been received and control has transferred. For certain Endoscopy, Instruments and Medical services, we may recognize sales over time as we satisfy performance obligations that may include an obligation to complete installation, provide training and perform ongoing services, generally performed within one year.
Orthopaedics
Orthopaedics products primarily include implants used in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries, and cervical and thoracolumbar systems that include fixation, minimally invasive and interbody systems used in spinal injury, complex spine and degenerative therapies. Substantially all Orthopaedics sales are recognized when we have received a purchase order and appropriate notification the product has been used or implanted. Substantially all Spinal Implants sales are recognized when a purchase order has been received and control has transferred. For certain Orthopaedic products in the "other" category, we recognize sales at a point in time, as well as over time for performance obligations that may include an obligation to complete installation and provide training and ongoing services. Performance obligations are generally satisfied within one year.
Costs to Obtain or Fulfill a Contract
We typically do not incur costs to fulfill a contract before a product or service is provided to a customer due to the nature of our products and services. Our costs to obtain contracts are typically in the form of sales commissions paid to employees or third-party agents. Certain sales commissions paid to employees prior to recognition of sales are recorded as deferred contract costs. We expense sales commissions associated with obtaining a contract at the time of the sale or as incurred as the amortization period is generally less than one year. These costs have been presented within selling, general and administrative expenses. On December 31, 2024 and 2023 deferred contracts costs recorded in our Consolidated Balance Sheets were not significant.
Contract Assets and Liabilities
Our contract assets primarily relate to conditional rights to consideration for work completed but not billed at the reporting date. On December 31, 2024 and 2023 contract assets recorded in our Consolidated Balance Sheets were not significant.
Our contract liabilities arise as a result of consideration received from customers at inception of contracts for certain businesses or where the timing of billing for services precedes satisfaction of our performance obligations. This occurs primarily when payment is received upfront for certain multi-period extended warranty service contracts. Our contract liabilities of $978 and $860 on
December 31, 2024 and 2023 are classified within accrued expenses and other liabilities and other noncurrent liabilities within our Consolidated Balance Sheets based on the timing of when we expect to complete our performance obligations. Changes in contract liabilities during the year were as follows:
2024
Beginning contract liabilities$860 
Revenue recognized from beginning of year contract liabilities(553)
Net advance consideration received during the period671 
Ending contract liabilities$978 
v3.25.0.1
Fair Value Measurements
 12 Months Ended
Dec. 31, 2024
Fair Value Disclosures [Abstract]  
Fair Value Measurements FAIR VALUE MEASUREMENTS
Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Financial assets and liabilities carried at fair value are classified in their entirety based on the lowest level of input and disclosed in one of the following three categories:
Level 1Quoted market prices in active markets for identical assets or liabilities.
Level 2Observable market-based inputs or unobservable inputs that are corroborated by market data.
Level 3Unobservable inputs reflecting our assumptions or external inputs from active markets.
Use of observable market data, when available, is required in making fair value measurements. When inputs used fall within different levels of the hierarchy, the level within which the fair value measurement is categorized is based on the lowest level input that is significant to the fair value measurement. We determine fair value for Level 1 instruments using exchange-traded prices for identical instruments. We determine fair value of Level 2 instruments using exchange-traded prices of similar instruments, where available, or utilizing other observable inputs that take into account our credit risk and that of our counterparties. Foreign currency exchange contracts and interest rate hedges, when outstanding, are included in Level 2 and are primarily valued using standard calculations and models that use readily observable market data as their basis. Our Level 3 liabilities are comprised of contingent consideration arising from recently completed acquisitions. We determine fair value of these Level 3 liabilities using a discounted cash flow technique. Significant unobservable inputs were used in our assessment of fair value, including assumptions regarding future business results, discount rates, discount periods and probability assessments based on the likelihood of reaching various targets. We remeasure the fair value of our assets and liabilities each reporting period. We record the changes in fair value within selling, general and administrative expense.
In 2024 we recorded $208 of contingent consideration related to various acquisitions described in Note 6.
In 2023 we recorded $192 of contingent consideration related to the acquisition of Cerus described in Note 6.
There were no significant transfers into or out of any level of the fair value hierarchy in 2024.
Assets Measured at Fair Value
20242023
Cash and cash equivalents$3,652 $2,971 
Short-term investments750 — 
Trading marketable securities259 209 
Level 1 - Assets$4,661 $3,180 
Available-for-sale marketable securities:
Corporate and asset-backed debt securities$53 $43 
United States agency debt securities1 4 
United States treasury debt securities34 31 
Certificates of deposit3 4 
Total available-for-sale marketable securities$91 $82 
Foreign currency exchange forward contracts225 116 
Level 2 - Assets$316 $198 
Total assets measured at fair value$4,977 $3,378 
Liabilities Measured at Fair Value
20242023
Deferred compensation arrangements$259 $209 
Level 1 - Liabilities$259 $209 
Foreign currency exchange forward contracts$77 $97 
Level 2 - Liabilities$77 $97 
Contingent consideration:
Beginning$289 $121 
Additions208 192 
Change in estimate and foreign exchange8 (2)
Settlements(53)(22)
Ending$452 $289 
Level 3 - Liabilities$452 $289 
Total liabilities measured at fair value$788 $595 
Fair Value of Available for Sale Securities by Maturity
20242023
Due in one year or less$47 $46 
Due after one year through three years$44 $36 
On December 31, 2024 the aggregate difference between the cost and fair value of available-for-sale marketable securities was nominal. Interest income on cash and cash equivalents, short-term investments and marketable securities income was $139, $75 and $25 in 2024, 2023 and 2022, which was recorded in other income (expense), net.
Our investments in available-for-sale marketable securities had a minimum credit quality rating of A2 (Moody's), A (Standard & Poor's) and A (Fitch). We do not plan to sell the investments, and it is not more likely than not that we will be required to sell the investments before recovery of their amortized cost basis, which may be maturity.
v3.25.0.1
Derivative Instruments
 12 Months Ended
Dec. 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Derivative Instruments DERIVATIVE INSTRUMENTS
We use operational and economic hedges, foreign currency exchange forward contracts, net investment hedges (both derivative and non-derivative financial instruments) and interest rate derivative instruments to manage the impact of currency exchange and interest rate fluctuations on earnings, cash flow and equity. We do not enter into derivative instruments for speculative purposes. We are exposed to potential credit loss in the event of nonperformance by counterparties on our outstanding derivative instruments but do not anticipate nonperformance by any of our counterparties. Should a counterparty default, our maximum loss exposure is the asset balance of the instrument.
Foreign Currency Hedges
2024Cash FlowNet InvestmentNon-DesignatedTotal
Gross notional amount$1,588 $2,338 $5,164 $9,090 
Maximum term in years9.7
Fair value:
Other current assets$43 $24 $119 $186 
Other noncurrent assets4 35 — 39 
Other current liabilities(29)— (41)(70)
Other noncurrent liabilities(3)(4)— (7)
Total fair value$15 $55 $78 $148 
2023Cash FlowNet InvestmentNon-DesignatedTotal
Gross notional amount$1,650 $1,662 $4,315 $7,627 
Maximum term in years2.9
Fair value:
Other current assets$24 $74 $16 $114 
Other noncurrent assets2 — — 2 
Other current liabilities(16)— (36)(52)
Other noncurrent liabilities(2)(43)— (45)
Total fair value$8 $31 $(20)$19 
We had €2.3 billion and €1.5 billion at December 31, 2024 and 2023 in certain forward currency contracts designated as net investment hedges, for which the maximum term is 9.7 years, to hedge a portion of our investments in certain of our entities with functional currencies denominated in Euros. In addition to these derivative financial instruments designated as net investment hedges, we had €5.0 billion and €4.9 billion at December 31, 2024 and 2023 of senior unsecured notes designated as net investment hedges to selectively hedge portions of our investment in certain international subsidiaries. The currency effects of our Euro-denominated senior unsecured notes are reflected in AOCI within shareholders' equity where they offset gains and losses recorded on our net investment in international subsidiaries.
In 2024 we settled certain foreign currency forward contracts designated as net investment hedges resulting in cash proceeds of $99. The amounts in AOCI related to settled net investment hedges will remain in AOCI until the hedged investment is either sold or substantially liquidated.
The total after-tax gain (loss) recognized in OCI related to designated net investment hedges was $325 in 2024.
Currency Exchange Rate Gains (Losses) Recognized in Net Earnings
Derivative InstrumentRecognized in:202420232022
Cash FlowCost of sales$31 $39 $23 
Net InvestmentOther income (expense), net35 34 39 
Non-DesignatedOther income (expense), net40 25 30 
Total$106 $98 $92 
Pretax gains (losses) on derivatives designated as cash flow hedges of $14 and net investment hedges of $43 recorded in AOCI are expected to be reclassified to cost of sales and other income (expense), net in earnings within 12 months of December 31, 2024. This cash flow hedge reclassification is primarily due to the sale of inventory that includes previously hedged purchases. A component of the AOCI amounts related to net investment hedges is reclassified over the life of the hedge instruments as we elected to exclude the initial value of the component related to the spot-forward difference from the effectiveness assessment.
Interest Rate Hedges
Pretax gains of $4 recorded in AOCI related to interest rate hedges closed in conjunction with debt issuances are expected to be reclassified to other income (expense), net in earnings within 12 months of December 31, 2024. The cash flow effect of interest rate hedges is recorded in cash flow from operations.
v3.25.0.1
Accumulated Other Comprehensive (Loss) Income (AOCI)
 12 Months Ended
Dec. 31, 2024
Reclassification Adjustments Out of Accumulated Other Comprehensive Income (AOCI) [Abstract]  
Accumulated Other Comprehensive (Loss) Income (AOCI) ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME (AOCI)
Marketable SecuritiesPension PlansHedgesFinancial Statement TranslationTotal
2022$(1)$31 $52 $(303)$(221)
OCI1 (67)27 (157)(196)
Income taxes— 12 (5)59 66 
Reclassifications to:
Cost of sales— — (39)— (39)
Other (income) expense, net— (5)(5)(34)(44)
Income taxes— 1 9 8 18 
Net OCI$1 $(59)$(13)$(124)$(195)
2023$— $(28)$39 $(427)$(416)
OCI— 43 26 236 305 
Income taxes— (11)(7)(110)(128)
Reclassifications to:
Cost of sales— — (31)— (31)
Other (income) expense, net— — (4)(35)(39)
Income taxes— — 8 8 16 
Net OCI$— $32 $(8)$99 $123 
2024$— $4 $31 $(328)$(293)
v3.25.0.1
Acquisitions
 12 Months Ended
Dec. 31, 2024
Business Combinations [Abstract]  
Acquisitions ACQUISITIONS
We acquire stock in companies and various assets that continue to support our capital deployment and product development strategies. Cash paid for acquisitions, net of cash acquired was $1,628 and $390 in 2024 and 2023.
In 2024 we completed various acquisitions for total consideration that includes $1,628 in upfront payments, net of cash acquired, and $400 contingent upon the achievement of certain commercial or clinical milestones. The combined acquisition-date fair values of the contingent milestone payments totaled $208. The acquired companies expand the product portfolios of our Instruments, Endoscopy, Medical and Neuro Cranial businesses within MedSurg and Neurotechnology and our Trauma and Extremities and Joint Replacement businesses within Orthopaedics. The purchase price allocation for our acquisitions are based on preliminary valuations, primarily related to developed technology
and customer relationships. Goodwill attributable to the acquisitions reflects the strategic benefits of expanding our market presence, diversifying our product portfolio and advancing innovations. This goodwill is not deductible for tax purposes.
On May 2, 2023 we acquired Cerus for net cash consideration of $289 and up to $225 in future milestone payments that had a fair value of $192 at the acquisition date. Cerus designs, develops and manufactures neurovascular products used for the treatment of hemorrhagic stroke. Cerus is part of our Neurovascular business within MedSurg and Neurotechnology. Goodwill attributable to the acquisition is not deductible for tax purposes.
The purchase price allocations for the acquisitions completed in 2024 and Cerus are:
Purchase Price Allocation of Acquired Net Assets
20242023
TotalCerus
Tangible assets acquired:
Accounts receivable$46 $1 
Inventory112 2 
Deferred income tax assets28 4 
Other assets27 1 
Debt(42)— 
Deferred income tax liabilities(205)(60)
Other liabilities(102)(22)
Intangible assets:
Developed technologies596 240 
Customer relationships214 — 
Patents6 — 
Trademarks2 — 
Goodwill1,154 315 
Purchase price, net of cash acquired of $57 and $7
$1,836 $481 
Weighted-average amortization period at acquisition (years):
Developed technologies1213
Customer relationships14— 
Patents12— 
Trademarks5— 
The purchase price allocation for Cerus was finalized in the second quarter 2024 with no material adjustments.
v3.25.0.1
Contingencies and Commitments
 12 Months Ended
Dec. 31, 2024
Commitments and Contingencies Disclosure [Abstract]  
Contingencies and Commitments CONTINGENCIES AND COMMITMENTS
We are involved in various ongoing proceedings, legal actions and claims arising in the normal course of business, including proceedings related to product, labor, intellectual property and other matters, the most significant of which are more fully described below. The outcomes of these matters will generally not be known for prolonged periods of time. In certain of the legal proceedings the claimants seek damages as well as other compensatory and equitable relief that could result in the payment of significant claims and settlements and/or the imposition of injunctions or other equitable relief. For legal matters for which management had sufficient information to reasonably estimate our future obligations, a liability representing management's best estimate of the probable loss, or the minimum of the range of probable losses when a best estimate within the range is not known, is recorded. The estimates are based on consultation with legal counsel, previous settlement experience and settlement strategies. If actual outcomes are less favorable than those estimated by management, additional expense may be incurred, which could unfavorably affect future operating results. We are self-insured for certain claims and expenses. The ultimate cost to us with respect to product liability claims could be materially different than the amount of the current estimates and accruals and could have a material adverse effect on our financial position, results of operations and cash flows.
We are currently investigating whether certain business activities in certain foreign countries violated provisions of the FCPA and have engaged outside counsel to conduct these investigations. We have been contacted by the United States Securities and Exchange Commission, United States Department of Justice and certain other regulatory authorities and are cooperating with these agencies. At this time we are unable to predict the outcome of the investigations or the potential impact, if any, on our financial statements.
We have conducted voluntary recalls of certain products, including our Rejuvenate and ABG II Modular-Neck hip stems and certain lot-specific sizes and offsets of LFIT Anatomic CoCr V40 Femoral Heads. Additionally, we are responsible for certain product liability claims, primarily related to certain hip products sold by Wright prior to its 2014 divestiture of the OrthoRecon business.
We have incurred, and expect to incur in the future, costs associated with the defense and settlement of claims and lawsuits. Based on the information that has been received related to the matters discussed above, we recorded charges of $17 in 2024 and our accrual for these matters was $202 at December 31, 2024, representing our best estimate of probable loss. The final outcomes of these matters are dependent on many factors that are difficult to predict. Accordingly the ultimate cost related to these matters may be materially different than the amount of our current estimate and accruals and could have a material adverse effect on our results of operations and cash flows.
Leases
We lease various manufacturing, warehousing and distribution facilities, administrative and sales offices as well as equipment under operating leases. We evaluate our contracts to identify leases, which is generally if there is an identified asset and we have the right to direct the use of and obtain substantially all of the economic benefit from the use of the identified asset. Certain of our lease agreements contain rent escalation clauses (including index-based escalations), rent holidays, capital improvement funding or other lease incentives. We recognize our minimum rental expense on a straight-line basis over the term of the lease beginning with the date of initial control of the asset. Right-of-use assets are recorded in Other noncurrent assets on our Consolidated Balance Sheets. Current and noncurrent lease liabilities are recorded in Accrued expenses and other liabilities and Other noncurrent liabilities, respectively.
We have made certain significant assumptions and judgments when recording leases. For all asset classes, we do not recognize a right-of-use asset and lease liability for short-term leases. We also do not separate non-lease components from lease components to which they relate and account for the combined lease and non-lease components as a single lease component. The determination of the discount rate used in a lease is our incremental borrowing rate which is based on what we would normally pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments.
20242023
Right-of-use assets $516 $494 
Lease liabilities, current $144 $143 
Lease liabilities, noncurrent $379 $356 
Other information:
Weighted-average remaining lease term (years)5.15.5
Weighted-average discount rate3.87 %3.87 %
Operating lease expense totaled $190, $172, and $149 in 2024, 2023 and 2022.
Future Obligations
We have purchase commitments for materials, supplies, services and property, plant and equipment as part of the normal course of business. In addition, we lease various manufacturing, warehousing and distribution facilities, administrative and sales offices as well as equipment under operating leases. Refer to Note 10 for more information on the debt obligations.
20252026202720282029Thereafter
Debt repayments$1,410 $1,000 $779 $1,823 $1,581 $7,109 
Purchase obligations$2,610 $157 $43 $16 $14 $15 
Minimum lease payments$156 $126 $91 $61 $43 $73 
Other Contractual Obligations and Commitments
We participate in a supplier financing program that enables our suppliers, at their sole discretion, to sell their Stryker receivables to a financial institution on a non-recourse basis in order to be paid earlier than our payment terms provide. Under this program, we agree to pay participating banks the stated amount of confirmed invoices from its designated suppliers on the original maturity dates of the invoices, generally within 90 days of the invoice date. We or the banks may agree to terminate the agreements with advance notice. Separately, the banks may have arrangements with the suppliers that provide them the option to request early payment from the bank for invoices confirmed by us. Our outstanding balances of confirmed invoices in the programs were $71 and $51 in 2024 and 2023 and are included within Accounts payable of the consolidated balance sheets.
2024
Beginning confirmed obligations$51 
Additions392 
Settlements(372)
Ending confirmed obligations$71 
v3.25.0.1
Goodwill and Other Intangible Assets
 12 Months Ended
Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Other Intangible Assets GOODWILL AND OTHER INTANGIBLE ASSETS
In our annual impairment tests of goodwill as of October 31, 2024 and 2023 we performed a quantitative assessment of the Spine reporting unit using a discounted cash flow analysis to estimate the fair value. Significant inputs to the analysis included assumptions for future revenue growth and operating margin. The analysis also included a rate to discount the estimated future cash flow projections to their present value based on the reporting unit’s estimated weighted average cost of capital.
In 2024 the carrying value of the Spine reporting unit exceeded its fair value and a charge of $273 was recognized in goodwill and other impairments in the Consolidated Statements of Earnings. The impairment charge for the Spine reporting unit was driven by a decrease in future product demand due to the competitive environment and an increase in the Spine reporting unit’s weighted average cost of capital. Subsequent to the annual goodwill impairment test management committed to a plan to sell certain assets associated with the Spinal Implants business (disposal group). Goodwill was allocated to the disposal group based on the relative fair values of the disposal group and the portion of the Spine reporting unit that will be retained. Goodwill allocated to the disposal group was tested for impairment which resulted in an impairment charge of $183 recognized in goodwill and other impairments. Refer to Note 16 for additional information on the assets classified as held for sale. For our annual impairment test in 2023 we also elected to perform a quantitative assessment. As a result of that assessment we concluded that the goodwill of the Spine reporting unit was not impaired in 2023.
For our other reporting units, we considered qualitative indicators of impairment as it was considered more likely than not that the fair values of those reporting units exceeded their respective carrying values. No impairment was identified for those reporting units in 2024 or 2023.
Future changes in the judgments, assumptions and estimates that are used in our impairment testing for goodwill, including discount and tax rates and future cash flow projections, could result in significantly different estimates of the fair values. A significant reduction in the estimated fair values could result in impairment charges that could materially affect our results of operations.
Goodwill of $117 previously reported within Orthopaedics was reclassified to MedSurg and Neurotechnology to reflect the reclassification of the interventional spine reporting unit from Orthopaedics to MedSurg and Neurotechnology to align with certain updates in our internal reporting structure. Goodwill recorded in the first three quarters of 2024 related to interventional spine is presented in the additions and adjustments line within MedSurg and Neurotechnology.
Changes in the Net Carrying Value of Goodwill by Segment
MedSurg and NeurotechnologyOrthopaedicsTotal
2022$7,935 $6,945 $14,880 
Additions and adjustments301 — 301 
Foreign exchange and other34 28 62 
2023$8,270 $6,973 $15,243 
Goodwill impairment— (456)(456)
Additions and adjustments852 300 1,152 
Foreign exchange and other86 (170)(84)
2024$9,208 $6,647 $15,855 
Summary of Other Intangible Assets
Gross
Carrying
Amount		Less
Accumulated
Amortization		Net
Carrying
Amount
Developed technologies
2024$5,698 $2,931 $2,767 
20235,769 2,815 2,954 
Customer relationships
2024$3,055 $1,636 $1,419 
20232,907 1,504 1,403 
Patents
2024$153 $136 $17 
2023329 302 27 
Trademarks
2024$413 $256 $157 
2023427 246 181 
In-process research and development
2024$34 $— $34 
202321 — 21 
Other
2024$63 $62 $1 
202396 89 7 
Total
2024$9,416 $5,021 $4,395 
20239,549 4,956 4,593 
Estimated Amortization Expense
20252026202720282029
$605 $550 $528 $480 $465 
v3.25.0.1
Capital Stock
 12 Months Ended
Dec. 31, 2024
Capital Stock [Abstract]  
Capital Stock CAPITAL STOCK
The aggregate number of shares of all classes of stock which we are authorized to issue is up to 1,000,500,000, divided into two classes consisting of 500,000 shares of $1 par value preferred stock and 1,000,000,000 shares of common stock with a par
value of $0.10. No shares of preferred stock were outstanding on December 31, 2024.
We made no repurchases of shares in 2024. The manner, timing and amount of repurchases are determined by management based on an evaluation of market conditions, stock price and other factors and are subject to regulatory considerations. Purchases are made from time-to-time in the open market, in privately negotiated transactions or otherwise. On December 31, 2024 the total dollar value of shares that could be purchased under our authorized repurchase program was $1,033.
Shares reserved for future compensation grants of our common stock were 18 million and 20 million on December 31, 2024 and 2023.
Stock Options
We measure the cost of employee stock options based on the grant-date fair value and recognize that cost using the straight-line method over the period in which a recipient is required to provide services in exchange for the options, typically the vesting period. The weighted-average fair value per share of options is estimated on the date of grant using the Black-Scholes option pricing model.
Option Value and Assumptions
202420232022
Weighted-average fair value per share$118.22 $83.59 $68.08 
Assumptions:
Risk-free interest rate4.3 %4.0 %1.8 %
Expected dividend yield1.1 %1.2 %1.0 %
Expected stock price volatility29.9 %29.0 %27.0 %
Expected option life (years)6.36.25.9
The risk-free interest rate for periods within the expected life of options granted is based on the United States Treasury yield curve in effect at the time of grant. Expected stock price volatility is based on the historical volatility of our stock. The expected option life, representing the period of time that options granted are expected to be outstanding, is based on historical option exercise and employee termination data.
2024 Stock Option Activity
Shares
(in millions)		Weighted-Average
Exercise Price		Weighted-Average
Remaining
Term (in years)		Aggregate
Intrinsic
 Value
Outstanding January 111.5 $189.70 
Granted1.3 339.72 
Exercised(1.7)134.86 
Canceled or forfeited(0.3)274.74 
Outstanding December 3110.8 $214.87 5.3$1,572.6 
Exercisable December 316.6 $175.39 3.1$1,223.3 
Options expected to vest3.9 $275.67 7.7$331.8 
The aggregate intrinsic value of options, which represents the cumulative difference between the fair market value of the underlying common stock and the option exercise prices, exercised was $362, $318 and $218 in 2024, 2023 and 2022. Exercise prices for options outstanding ranged from $92.24 to $339.77 on December 31, 2024. On December 31, 2024 there was $159 of unrecognized compensation cost related to nonvested stock options granted under the long-term incentive plans. That cost is expected to be recognized as expense over the weighted-average period of approximately 1.5 years.
Restricted Stock Units (RSUs) and Performance Stock Units (PSUs) Activity
Shares
(in millions)		Weighted-Average
Grant Date Fair Value
RSUsPSUsRSUsPSUs
Nonvested on January 10.7 0.2 $246.98 $250.17 
Granted0.3 0.1 332.64 305.99 
Vested(0.3)(0.1)244.18 233.95 
Canceled or forfeited— — 276.23 233.95 
Nonvested on December 310.7 0.2 $290.58 $287.51 
On December 31, 2024 there was $90 of unrecognized compensation cost related to nonvested RSUs. That cost is expected to be recognized as expense over the weighted-average period of approximately one year. The weighted-average grant date fair value per share of RSUs granted was $332.64 and $257.09 in 2024 and 2023. The fair value of RSUs and PSUs vested in 2024 was $81 and $23. On December 31, 2024 there was $23 of unrecognized compensation cost related to nonvested PSUs. That cost is expected to be recognized as expense over the weighted-average period of approximately one year.
Employee Stock Purchase Plans (ESPP)
Employees may participate in our ESPP provided they meet certain eligibility requirements. The purchase price for our common stock under the terms of the ESPP is defined as 95% of the closing stock price on the last trading day of a purchase period. We issued 173,708 and 190,524 shares under the ESPP in 2024 and 2023.
v3.25.0.1
Debt and Credit Facilities
 12 Months Ended
Dec. 31, 2024
Long-Term Debt, Unclassified [Abstract]  
Debt And Credit Facilities DEBT AND CREDIT FACILITIES
We have lines of credit issued by various financial institutions that are available to fund our day-to-day operating needs. Certain of our credit facilities require us to comply with financial and other covenants. We were in compliance with all covenants on December 31, 2024.
On December 31, 2024 there were no borrowings outstanding under our revolving credit facility or our commercial paper program which allows for maturities up to 397 days from the date of issuance. The maximum amount of our commercial paper that can be outstanding at any time is $2,250.
In May 2024 we repaid the outstanding $600 principal amount of the 3.375% senior unsecured notes due May 15, 2024. In September 2024 we issued $750 of 4.250% senior unsecured notes due September 11, 2029, €800 of 3.375% senior unsecured notes due September 11, 2032, $750 of 4.625% senior unsecured notes due September 11, 2034 and €600 of 3.625% senior unsecured notes due September 11, 2036. In November 2024 we repaid the outstanding €500 of floating rate senior notes and in December 2024 we repaid €850 of 0.250% senior unsecured notes. The following table summarizes our total debt at December 31:
Summary of Total Debt
RateDue20242023
Senior unsecured notes:
3.375%May 15, 2024$— $600 
VariousNovember 16, 2024— 554 
0.250%December 3, 2024— 940 
1.150%June 15, 2025649 648 
3.375%November 1, 2025750 749 
3.500%March 15, 2026998 997 
2.125%November 30, 2027777 828 
3.650%March 7, 2028598 598 
4.850%December 8, 2028596 596 
3.375%December 11, 2028621 661 
0.750%March 1, 2029828 883 
4.250%September 11, 2029743 — 
1.950%June 15, 2030993 991 
2.625%November 30, 2030669 713 
1.000%December 3, 2031772 823 
3.375%September 11, 2032824 — 
4.625%September 11, 2034740 — 
3.625%September 11, 2036613 — 
4.100%April 1, 2043393 393 
4.375%May 15, 2044396 396 
4.625%March 15, 2046984 983 
2.900%June 15, 2050643 642 
Other10 — 
Total debt$13,597 $12,995 
Less current maturities1,409 2,094 
Total long-term debt$12,188 $10,901 
Unamortized debt issuance costs$63 $50 
Borrowing capacity on existing facilities$2,160 $2,160 
Fair value of senior unsecured notes$12,780 $12,252 
The fair value of the senior unsecured notes was estimated using quoted interest rates, maturities and amounts of borrowings based on quoted active market prices and yields that took into account the underlying terms of the debt instruments. Substantially all of our debt is classified within Level 2 of the fair value hierarchy.
Interest expense on outstanding debt and credit facilities, including required fees incurred, that were included in other income (expense), net, totaled $396, $356, and $337 in 2024, 2023 and 2022.
v3.25.0.1
Income Taxes
 12 Months Ended
Dec. 31, 2024
Income Tax Disclosure [Abstract]  
Income Taxes INCOME TAXES
Our effective tax rate was 14.3%, 13.8% and 12.1% for 2024, 2023 and 2022. The effective income tax rate for 2024 increased from 2023 due to the 2024 deferred tax benefit on the outside basis difference related to the anticipated sale of the Spinal Implants business partially offset by the 2023 tax effect related to transfers of intellectual property between tax jurisdictions. The effective income tax rate for 2023 increased from 2022 due to the 2022 effective settlement of the United States federal income tax audit for years 2014 through 2018 and the 2022 reversal of deferred income tax on undistributed earnings of foreign subsidiaries partially offset by the 2023 tax effect related to transfers of intellectual property between tax jurisdictions. Additionally, the effective income tax rates for 2024, 2023 and 2022 reflect the continued lower effective income tax rates as a result of our European operations and certain discrete tax items.
Effective Income Tax Rate Reconciliation
202420232022
United States federal statutory rate21.0 %21.0 %21.0 %
United States state and local income taxes, less federal deduction1.1 1.1 2.0 
Foreign income tax at rates other than 21%(4.1)(6.8)(4.1)
Tax related to repatriation of foreign earnings0.3 1.2 (2.4)
United States research and development credits(1.4)(1.2)(1.5)
Intellectual property transfers— (3.3)0.1 
United States federal audit settlement— — (6.1)
Goodwill impairment2.8 — 1.7 
Outside basis difference related to the anticipated sale of the Spinal Implants business(4.9)— — 
Other(0.5)1.8 1.4 
Effective income tax rate14.3 %013.8 %12.1 %
Earnings Before Income Taxes 
202420232022
United States$523 $701 $407 
International2,969 2,972 2,276 
Total$3,492 $3,673 $2,683 
Components of Income Tax Expense (Benefit)
Current income tax expense (benefit):202420232022
United States federal$490 $236 $(76)
United States state and local90 48 64 
International289 430 279 
Total current income tax expense$869 $714 $267 
Deferred income tax expense (benefit):
United States federal$(462)$(212)$(179)
United States state and local(76)(20)(30)
International168 26 267 
Total deferred income tax expense (benefit)$(370)$(206)$58 
Total income tax expense$499 $508 $325 
Interest included in other income (expense), net was expense of $13 and $1 in 2024 and 2023 and income of $71 in 2022. The United States federal deferred income tax expense (benefit) includes the utilization of net operating loss carryforwards of $9, $189 and $56 in 2024, 2023 and 2022.
Deferred Income Tax Assets and Liabilities
Deferred income tax assets:20242023
Inventories$551 $521 
Other accrued expenses207 253 
Depreciation and amortization715 918 
State income taxes167 150 
Share-based compensation100 86 
Research and development capitalization408 295 
International interest expense carryforwards52 46 
Net operating loss and credit carryforwards410 385 
Outside basis difference related to the anticipated sale of the Spinal Implants business170 — 
Other310 235 
Total deferred income tax assets$3,090 $2,889 
Less valuation allowances(228)(223)
Net deferred income tax assets$2,862 $2,666 
Deferred income tax liabilities:
Depreciation and amortization$(1,141)$(1,012)
Undistributed earnings(61)(47)
Total deferred income tax liabilities$(1,202)$(1,059)
Net deferred income tax assets$1,660 $1,607 
Reported as:
Noncurrent deferred income tax assets$1,742 $1,670 
Noncurrent liabilities—Other liabilities(82)(63)
Total$1,660 $1,607 
Accrued interest was $71 and $67 on December 31, 2024 and 2023 which was reported in accrued expenses and other liabilities and other noncurrent liabilities.
United States federal loss carryforwards of $335, with $70 of associated deferred tax asset and with $2 being subject to a valuation allowance, begin to expire in 2025. United States state loss carryforwards of $3,480, with $85 associated deferred tax asset and with $49 being subject to a valuation allowance, begin to expire in 2025. International loss carryforwards of $269, with $69 of associated deferred tax asset and with $63 being subject to a valuation allowance, begin to expire in 2026; however, some have no expiration. We also have tax credit carryforwards of $204 with $83 being subject to a full valuation allowance. The credits with a full valuation allowance begin to expire in 2025.
We recorded deferred income tax on undistributed earnings of foreign subsidiaries not determined to be indefinitely reinvested. In 2022 it was determined that, based on our revised capital plan, certain cash outside the United States would no longer need to be repatriated during the period previously contemplated. As a result deferred taxes of $71 that were recorded on the associated earnings were reversed. The amount of undistributed earnings of foreign subsidiaries determined to be indefinitely reinvested at December 31, 2024 was approximately $10 billion. Determination of the total amount of unrecognized deferred income tax on undistributed earnings of foreign subsidiaries is not practicable.
Uncertain Income Tax Positions
 20242023
Beginning uncertain tax positions$371 $286 
Increases related to current year income tax positions18 102 
Increases related to prior year income tax positions— 10 
Decreases related to prior year income tax positions(4)(33)
Settlements of income tax audits(21)(1)
Statute of limitations expirations and other(3)— 
Foreign currency translation(12)7 
Ending uncertain tax positions$349 $371 
Reported as:
Noncurrent liabilities—Income taxes$349 $371 
Our income tax expense would have been reduced by $224 and $248 in 2024 and 2023 had these uncertain income tax positions been favorably resolved. It is reasonably possible that the amount of unrecognized tax benefits will significantly change due to one or more of the following events in the next 12 months: expiring statutes, audit activity, tax payments, competent authority proceedings related to transfer pricing or final decisions in matters that are the subject of controversy in various taxing jurisdictions in which we operate, including inventory transfer pricing, cost sharing, product royalty and foreign branch arrangements. We are not able to reasonably estimate the amount or the future periods in which changes in unrecognized tax benefits may be resolved. Interest incurred associated with uncertain tax positions is included in other income (expense), net.
In the normal course of business, income tax authorities in various income tax jurisdictions both within the United States and internationally conduct routine audits of our income tax returns filed in prior years. These audits are generally designed to determine if individual income tax authorities are in agreement with our interpretations of complex income tax regulations regarding the allocation of income to the various income tax jurisdictions. Any income tax audit assessment or draft income tax audit assessment received at the conclusion of an audit is reviewed and evaluated for proper financial statement treatment. We have not received any audit assessments or draft assessments that have not been reviewed and evaluated.
Income tax expense in 2022 decreased $162 due to the effective settlement of the United States federal income tax audit for years 2014 through 2018. In addition 2022 other income (expense), net includes a benefit of $50 related to the release of accrued interest
associated with this settlement. Income tax years are open from 2019 through the current year for the United States federal jurisdiction. Income tax years open for our other major jurisdictions range from 2010 through the current year.
v3.25.0.1
Retirement Plans
 12 Months Ended
Dec. 31, 2024
Retirement Benefits [Abstract]  
Retirement Plans RETIREMENT PLANS
Defined Contribution Plans
We provide certain employees with defined contribution plans and other types of retirement plans. A portion of our retirement plan expense under the defined contribution plans is funded with Stryker common stock. The use of Stryker common stock represents a non-cash operating activity that is not reflected in our Consolidated Statements of Cash Flows.
202420232022
Plan expense$376 $327 $305 
Expense funded with Stryker common stock62 57 41 
Stryker common stock held by plan:
Dollar amount$781 $649 $522 
Shares (in millions)2.2 2.2 2.1 
Value as a percentage of total plan assets10 %10 %10 %
Defined Benefit Plans
Certain of our subsidiaries have both funded and unfunded defined benefit pension plans covering some or all of their employees. The majority of our defined benefit pension plans have projected benefit obligations in excess of plan assets.
Discount Rate
The discount rates were selected using a hypothetical portfolio of high quality bonds on December 31 that would provide the necessary cash flows to match our projected benefit payments.
Expected Return on Plan Assets
The expected return on plan assets is determined by applying the target allocation in each asset category of plan investments to the anticipated return for each asset category based on historical and projected returns.
Components of Net Periodic Pension Cost
Net periodic benefit cost:202420232022
Service cost$(39)$(32)$(56)
Interest cost(21)(23)(10)
Expected return on plan assets19 18 15 
Amortization of prior service credit1 1 1 
Recognized actuarial gain (loss)(1)4 (9)
Net periodic benefit cost$(41)$(32)$(59)
Changes in assets and benefit obligations recognized in OCI:
Net actuarial gain (loss)$43 $(67)$244 
Recognized net actuarial (gain) loss1 (4)9 
Prior service credit and transition amount(1)(1)(1)
Total recognized in other comprehensive income (loss)$43 $(72)$252 
Total recognized in net periodic benefit cost and OCI$2 $(104)$193 
Weighted-average rates used to determine net periodic benefit cost:
Discount rate2.8 %3.3 %1.1 %
Expected return on plan assets4.3 %4.2 %3.1 %
Rate of compensation increase3.0 %3.0 %2.6 %
Weighted-average discount rate used to determine projected benefit obligations2.9 %2.8 %3.3 %
The actuarial gain (loss) for all pension plans was primarily related to a change in the discount rate used to measure the benefit obligations of those plans.
Investment Strategy
The investment strategy for our defined benefit pension plans is to meet the liabilities of the plans as they fall due and to maximize the return on invested assets within appropriate risk
tolerances.
20242023
Fair value of plan assets$492 $485 
Benefit obligations(782)(826)
Funded status$(290)$(341)
Reported as:
Noncurrent assets—other assets$48 $21 
Current liabilities—accrued compensation(3)(3)
Noncurrent liabilities—other liabilities(335)(359)
Pre-tax amounts recognized in AOCI:
Unrecognized net actuarial gain (loss)6 (39)
Unrecognized prior service credit8 11 
Total$14 $(28)
Change in Benefit Obligations
20242023
Beginning projected benefit obligations$826 $673 
Service cost39 32 
Interest cost21 23 
Foreign exchange impact(52)32 
Employee contributions7 7 
Actuarial (gains) losses(40)79 
Benefits paid(19)(20)
Ending projected benefit obligations$782 $826 
Ending accumulated benefit obligations$748 $790 
Change in Plan Assets
20242023
Beginning fair value of plan assets$485 $420 
Actual return22 29 
Employer contributions23 23 
Employee contributions7 7 
Foreign exchange impact(31)22 
Benefits paid(14)(16)
Ending fair value of plan assets$492 $485 
Allocation of Plan Assets
2025 Target2024 Actual2023 Actual
Equity securities24 %28 %28 %
Debt securities44 40 37 
Other32 32 35 
Total100 %100 %100 %
Valuation of Plan Assets
2024Level 1Level 2Level 3Total
Cash and cash equivalents$17 $— $— $17 
Equity securities8 125 — 133 
Debt securities2 203 — 205 
Other4 76 57 137 
Total$31 $404 $57 $492 
2023Level 1Level 2Level 3Total
Cash and cash equivalents$15 $— $— $15 
Equity securities20 130 — 150 
Debt securities2 185 — 187 
Other5 63 65 133 
Total$42 $378 $65 $485 
Our Level 3 pension plan assets primarily include guaranteed investment contracts with insurance companies. The insurance contracts guarantee us principal repayment and a fixed rate of return. The $8 decrease in Level 3 pension plan assets is primarily driven by the change in the corresponding pension liability. We expect to contribute $21 to our defined benefit pension plans in 2025.
Estimated Future Benefit Payments
202520262027202820292030-2034
$24 $23 $25 $26 $27 $171 
v3.25.0.1
Summary of Quarterly Data (Unaudited)
 12 Months Ended
Dec. 31, 2024
Quarterly Financial Data [Abstract]  
Summary of Quarterly Data (Unaudited) SUMMARY OF QUARTERLY DATA (UNAUDITED)
2024 QuartersMar 31Jun 30Sep 30Dec 31
Net sales$5,243 $5,422 $5,494 $6,436 
Gross profit3,333 3,416 3,517 4,174 
Earnings before income taxes923 998 1,043 528 
Net earnings788 825 834 546 
Net earnings per share of common stock:
Basic$2.07 $2.17 $2.18 $1.43 
Diluted$2.05 $2.14 $2.16 $1.41 
Dividends declared per share of common stock$0.80 $0.80 $0.80 $0.84 
2023 QuartersMar 31Jun 30Sep 30Dec 31
Net sales$4,778 $4,996 $4,909 $5,815 
Gross profit3,016 3,181 3,158 3,703 
Earnings before income taxes679 899 869 1,226 
Net earnings592 738 692 1,143 
Net earnings per share of common stock:
Basic$1.56 $1.95 $1.82 $3.01 
Diluted$1.54 $1.93 $1.80 $2.98 
Dividends declared per share of common stock$0.75 $0.75 $0.75 $0.80 
v3.25.0.1
Segment and Geographic Data
 12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
Segment and Geographic Data SEGMENT AND GEOGRAPHIC DATA
On January 1, 2024 we adopted ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures which expands disclosure requirements to require entities to disclose significant segment expenses that are regularly provided to or easily computed from information regularly provided to the chief operating decision maker. We have updated our disclosures to include our significant segment expenses that are regularly provided to our chief operating decision maker (CODM).
We segregate our operations into two reportable business segments: (i) MedSurg and Neurotechnology and (ii) Orthopaedics which aligns to our internal reporting structure and how our CODM assesses the performance of and allocates resources. The CODM is the Chief Executive Officer. The CODM makes decisions on resource allocation, assesses performance of the business, and monitors budget versus actual results using segment operating income. Our reportable segments and related disclosures reflect certain reclassifications of prior year amounts from our Orthopaedics segment to our MedSurg and Neurotechnology segment due to changes in our internal reporting structure.
The Corporate and Other category shown in the table below includes corporate and administration, corporate initiatives and share-based compensation, which includes compensation related to employee stock options, restricted stock units and performance stock unit grants and director stock options and restricted stock unit grants.
Segment Results202420232022
MedSurg and Neurotechnology$13,518 $12,163 $10,893 
Orthopaedics$9,077 8,335 7,556 
Net sales$22,595 $20,498 $18,449 
MedSurg and Neurotechnology$5,320 $4,876 $4,637 
Orthopaedics$2,400 2,254 1,920 
Cost of sales $7,720 $7,130 $6,557 
MedSurg and Neurotechnology$784 $702 $682 
Orthopaedics$540 508 477 
Segment research, development and engineering expenses$1,324 $1,210 $1,159 
MedSurg and Neurotechnology$3,203 $2,934 $2,564 
Orthopaedics$3,111 2,922 2,608 
Segment selling, general and administrative expenses $6,314 $5,856 $5,172 
MedSurg and Neurotechnology$208 $181 $178 
Orthopaedics433 386 350 
Segment depreciation and amortization $641 $567 $528 
Corporate and Other162 139 123 
Amortization of intangible assets623 635 627 
Total depreciation and amortization$1,426 $1,341 $1,278 
MedSurg and Neurotechnology$4,004 $3,470 $2,831 
Orthopaedics2,591 2,265 2,202 
Segment operating income$6,595 $5,735 $5,033 
Items not allocated to segments:
Corporate and Other$(880)$(780)$(649)
Inventory stepped up to fair value(46)— — 
Acquisition and integration-related charges(108)(20)(138)
Amortization of intangible assets(623)(635)(627)
Structural optimization and other special charges(138)(170)(295)
Goodwill and other impairments(977)(36)(270)
Medical device regulation(58)(96)(140)
Recall-related matters(40)(18)15 
Regulatory and legal matters(36)(92)(76)
Consolidated operating income$3,689 $3,888 $2,841 
Segment Assets and Capital Spending
Assets:20242023
MedSurg and Neurotechnology$23,115 $20,804 
Orthopaedics18,507 18,023 
Total segment assets$41,622 $38,827 
Corporate and Other1,349 1,085 
Total assets$42,971 $39,912 
Purchases of property, plant and equipment:202420232022
Orthopaedics$230 $179 $173 
MedSurg and Neurotechnology276 183 175 
Total segment purchases of property, plant and equipment$506 $362 $348 
Corporate and Other249 213 240 
Total purchases of property, plant and equipment$755 $575 $588 
We measure the financial results of our reportable segments using an internal performance measure that excludes acquisition and integration-related charges, structural optimization and other special charges, goodwill and other impairments, reserves for certain product recall matters and reserves for certain legal and regulatory matters. Identifiable assets are those assets used exclusively in the operations of each business segment or allocated when used jointly. Corporate assets are principally property, plant and equipment and noncurrent assets.
The countries in which we have local revenue generating operations have been combined into the following geographic areas: the United States; Europe, Middle East, Africa; Asia Pacific; and other foreign countries, which include Canada and countries in the Latin American region. Net sales are reported based on the geographic area of the Stryker location where the sales to the customer originated.
Geographic Information
Net SalesNet Property, Plant and Equipment
20242023202220242023
United States$16,943 $15,257 $13,638 $1,997 $1,874 
Europe, Middle East, Africa2,897 2,618 2,348 1,260 1,151 
Asia Pacific2,020 1,946 1,885 75 77 
Other countries735 677 578 116 113 
Total$22,595 $20,498 $18,449 $3,448 $3,215 
v3.25.0.1
Asset Impairments
 12 Months Ended
Dec. 31, 2024
Property, Plant and Equipment [Abstract]  
Asset Impairments ASSET IMPAIRMENTSDuring 2024, 2023 and 2022 we recorded impairment charges of $159, $36 and $54 to write off long-lived and intangible assets excluding long-lived assets held for sale which included charges related to certain product line exits
v3.25.0.1
Assets Held for Sale
 12 Months Ended
Dec. 31, 2024
Discontinued Operations and Disposal Groups [Abstract]  
Assets Held for Sale ASSETS HELD FOR SALE
During the fourth quarter 2024 management committed to a plan to sell certain assets associated with the Spinal Implants business and such assets were classified as held for sale beginning November 2024. As a result we recognized an estimated loss of $362 to record the disposal group at its fair value less cost to sell within goodwill and other impairments in our Consolidated Statements of Earnings. The fair value of the disposal group was measured using a discounted cash flow analysis based upon unobservable inputs, such as estimated selling price derived from Company-specific information, market conditions and the rate used to discount the estimated future cash flows to their present value based on factors including the disposal group’s cost of equity and market yield rates, which are Level 3 inputs. Future changes in the judgments, assumptions and estimates that are used in our fair value estimate, including discount rates and cash flow projections, could result in a significantly different estimate of fair value. In January 2025 we entered into a definitive agreement to sell the Spinal Implants disposal group as further discussed in Note 17. The terms of the definitive agreement were materially the same as those considered as inputs to the valuation of the disposal group at December 31, 2024. A change in the amount or timing of consideration received could increase the fair value by up to $84 or decrease the fair value by up to $218.
A valuation allowance was recorded to reflect the estimated loss on the disposal group. The assets associated with the Spinal Implants disposal group are reported in our Orthopaedics segment. The assets and liabilities held for sale are classified within prepaid expenses and other current assets and accrued expenses and other liabilities in our Consolidated Balance Sheets and included the following as of December 31, 2024:
2024
Accounts receivable, net$62 
Total inventories 183
Prepaid expenses and other current assets 10
Property, plant and equipment, net 51
Other intangibles, net 326
Noncurrent deferred income tax assets 9
Other noncurrent assets 171
Valuation allowance (362)
Total assets held for sale $450 
Accounts payable $28 
Accrued compensation 26
Accrued expenses and other liabilities 29
Other noncurrent liabilities 21
Total liabilities held for sale$104 
v3.25.0.1
Subsequent Events
 12 Months Ended
Dec. 31, 2024
Subsequent Events [Abstract]  
Subsequent Events SUBSEQUENT EVENTS
In January 2025 we announced a definitive merger agreement to acquire all of the issued and outstanding shares of common stock of Inari Medical, Inc. (Inari). Pursuant to the agreement we commenced a tender offer to purchase all of the outstanding shares of common stock of Inari for $80 per share in cash, or an aggregate purchase price of approximately $4.9 billion. The boards of directors of both Stryker and Inari have unanimously approved the transaction. We expect the acquisition to close in the first quarter of 2025, subject to completion of the tender offer and other customary closing conditions. Inari’s product portfolio includes mechanical thrombectomy solutions for peripheral vascular diseases such as deep vein thrombosis and pulmonary embolism. Following closing, we plan to integrate Inari into our MedSurg and Neurotechnology segment.
In January 2025 we announced a definitive agreement to sell our United States Spinal Implants business to Viscogliosi Brothers, LLC. The definitive agreement includes a binding offer to sell our Spinal Implants business in France, subject to required consultations with employees and employee representatives. We expect the sale of the United States business to close in the first half of 2025, subject to customary closing conditions.
In February 2025 we issued $500 of 4.550% senior unsecured notes due February 10, 2027, $700 of 4.700% senior unsecured notes due February 10, 2028, $800 of 4.850% senior unsecured notes due February 10, 2030 and $1,000 of 5.200% senior unsecured notes due February 10, 2035. We intend to use the net proceeds from the notes due in 2030 and 2035, together with cash on hand or other immediately available funds, to consummate the Inari Tender Offer and to pay related fees and expenses. We intend to use the net proceeds from the notes due in 2027 and 2028 for general corporate purposes, which may include working capital, other acquisitions and repayment of indebtedness.
v3.25.0.1
Schedule II Valuation and Qualifying Accounts (Notes)
 12 Months Ended
Dec. 31, 2024
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]  
SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure
(a) 1.Financial Statements
The following Consolidated Financial Statements are set forth in Part II, Item 8 of this report.
Report of Independent Registered Public Accounting Firm
Consolidated Statements of Earnings for 2024, 2023 and 2022
Consolidated Statements of Comprehensive Income for 2024, 2023 and 2022
Consolidated Balance Sheets on 2024 and 2023
Consolidated Statements of Shareholders’ Equity for 2024, 2023 and 2022
Consolidated Statements of Cash Flows for 2024, 2023 and 2022
Notes to Consolidated Financial Statements
(a) 2.Financial Statement Schedules
The Consolidated Financial Statement schedule of Stryker Corporation and its subsidiaries is:
SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS
  AdditionsDeductions 
DescriptionBalance at
Beginning
of Period		Charged to
Costs &
Expenses		Uncollectible Amounts Written Off, Net of RecoveriesEffect of Changes in Foreign Currency Exchange RatesBalance
at End
of Period
DEDUCTED FROM ASSET ACCOUNTS
Allowance for Doubtful Accounts:
Year ended December 31, 2024
$182 $69 $36 $2 $213 
Year ended December 31, 2023
$154 $69 $40 $1 $182 
Year ended December 31, 2022
$167 $41 $52 $2 $154 
All other schedules for which provision is made in the applicable accounting regulation of the United States Securities and Exchange Commission are not required under the related instructions or are inapplicable and, therefore, have been omitted.
(a) 3.Exhibits
v3.25.0.1
Pay vs Performance Disclosure - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Dec. 31, 2024
Sep. 30, 2024
Jun. 30, 2024
Mar. 31, 2024
Dec. 31, 2023
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Pay vs Performance Disclosure                      
Net earnings $ 546 $ 834 $ 825 $ 788 $ 1,143 $ 692 $ 738 $ 592 $ 2,993 $ 3,165 $ 2,358
v3.25.0.1
Insider Trading Arrangements
 3 Months Ended
Dec. 31, 2024
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
v3.25.0.1
Insider Trading Policies and Procedures
 12 Months Ended
Dec. 31, 2024
Insider Trading Policies and Procedures [Line Items]  
Insider Trading Policies and Procedures Adopted true
v3.25.0.1
Cybersecurity Risk Management and Strategy Disclosure
 12 Months Ended
Dec. 31, 2024
Cybersecurity Risk Management, Strategy, and Governance [Line Items]  
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block] We review cybersecurity risk as part of our overall enterprise risk management program. This ensures that cybersecurity risk management remains a top priority in our business strategy and operations.
Cybersecurity Risk Management Processes Integrated [Flag] true
Cybersecurity Risk Management Processes Integrated [Text Block] Primary management responsibility for assessing, monitoring and managing our cybersecurity risks rests with our chief information security officer ("CISO"). Our current CISO has over 30 years of experience in information technology including over 20 years in cybersecurity and oversees a team of cybersecurity professionals with over 140 security, risk, and compliance certifications. The CISO is regularly informed about recent developments in cybersecurity, including potential threats and innovative risk management techniques.
Cybersecurity Risk Management Third Party Engaged [Flag] true
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag] true
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag] false
Cybersecurity Risk Board of Directors Oversight [Text Block] Cybersecurity risks are overseen by the full Board of Directors and the Audit Committee. The Audit Committee is central to the Board of Directors’ oversight of cybersecurity risks and bears the primary responsibility for overseeing cybersecurity risk. The Audit Committee actively participates in strategic decisions related to cybersecurity, offering guidance and approval for major cybersecurity initiatives. This involvement ensures that cybersecurity considerations are integrated into our broader strategic objectives.
Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block] Cybersecurity risks are overseen by the full Board of Directors and the Audit Committee. The Audit Committee is central to the Board of Directors’ oversight of cybersecurity risks and bears the primary responsibility for overseeing cybersecurity risk. The Audit Committee actively participates in strategic decisions related to cybersecurity, offering guidance and approval for major cybersecurity initiatives. This involvement ensures that cybersecurity considerations are integrated into our broader strategic objectives.
Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]
Our CISO provides comprehensive updates to the Audit Committee quarterly and the full Board of Directors periodically. These briefings include a range of topics, including:
•Current cybersecurity landscape and emerging threats;
•Status of ongoing cybersecurity initiatives and strategies;
•Incident reports and learnings from any cybersecurity events;
•Metrics demonstrating company and industry-standard prevention of common threats; and
•Regulatory changes impacting cybersecurity requirements and strategy.
Cybersecurity Risk Role of Management [Text Block]
Primary management responsibility for assessing, monitoring and managing our cybersecurity risks rests with our chief information security officer ("CISO"). Our current CISO has over 30 years of experience in information technology including over 20 years in cybersecurity and oversees a team of cybersecurity professionals with over 140 security, risk, and compliance certifications. The CISO is regularly informed about recent developments in cybersecurity, including potential threats and innovative risk management techniques.
The CISO implements and oversees processes for the regular monitoring of our information systems. We use various tools and methodologies to manage cybersecurity risk that are tested regularly. We also monitor and evaluate our cybersecurity posture and performance on an ongoing basis through regular vulnerability scans, penetration tests and threat intelligence feeds. In addition, we engage third-party consultants to conduct annual cybersecurity assessments and to conduct audits for compliance with regulatory, Sarbanes-Oxley Act, Service Organization Control Type 2 and International Organization for Standardization standards. We also engage third parties to assess our cybersecurity maturity and risk management programs.
We use a cross-departmental approach to addressing cybersecurity risk, with our cybersecurity, product security and legal teams presenting quarterly on key topics to a committee of leaders in finance, regulatory, and corporate affairs functions. This leadership committee meets quarterly to ensure that we have input and oversight from critical stakeholders into our cybersecurity program and evolving issues.
The CISO oversees a training and awareness program for employees to take part in protecting the Company against cybersecurity risks. We have implemented annual mandatory security education to help employees understand cybersecurity risks and comply with our cybersecurity policies. Additionally, we provide frequent communications around pertinent cybersecurity topics and policies to all employees. We also provide additional
cybersecurity and data protection training to employees in certain roles.
As part of our cybersecurity risk management program, we also conduct cybersecurity and privacy assessments on all third parties who integrate with Stryker’s data, network, systems and products. We use a combination of internal and external tools to confirm that these third parties meet our security requirements. We leverage standard industry threat model and privacy impact assessment concepts to confirm that data minimization and adequate data protections are in place. We perform supplemental reviews as necessary, commensurate with the risk associated with each vendor.
In the event of a cybersecurity incident, we have an incident response plan that includes immediate actions to mitigate the impact and long-term strategies for remediation and prevention of future incidents. The cybersecurity and product security teams routinely practice this plan with functions across the organization. We conduct tabletop exercises with senior management, during which we practice the procedures in place to ensure that potentially material cybersecurity risks and incidents are escalated to management and the Board of Directors where applicable.
Cybersecurity Risk Management Positions or Committees Responsible [Flag] true
Cybersecurity Risk Management Positions or Committees Responsible [Text Block] Primary management responsibility for assessing, monitoring and managing our cybersecurity risks rests with our chief information security officer ("CISO")
Cybersecurity Risk Management Expertise of Management Responsible [Text Block] Our current CISO has over 30 years of experience in information technology including over 20 years in cybersecurity and oversees a team of cybersecurity professionals with over 140 security, risk, and compliance certifications. The CISO is regularly informed about recent developments in cybersecurity, including potential threats and innovative risk management techniques.
Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]
The CISO oversees a training and awareness program for employees to take part in protecting the Company against cybersecurity risks. We have implemented annual mandatory security education to help employees understand cybersecurity risks and comply with our cybersecurity policies. Additionally, we provide frequent communications around pertinent cybersecurity topics and policies to all employees. We also provide additional
cybersecurity and data protection training to employees in certain roles.
As part of our cybersecurity risk management program, we also conduct cybersecurity and privacy assessments on all third parties who integrate with Stryker’s data, network, systems and products. We use a combination of internal and external tools to confirm that these third parties meet our security requirements. We leverage standard industry threat model and privacy impact assessment concepts to confirm that data minimization and adequate data protections are in place. We perform supplemental reviews as necessary, commensurate with the risk associated with each vendor.
Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag] true
v3.25.0.1
Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2024
Accounting Policies [Abstract]  
Nature of Operations Stryker (the "Company," "we," "us," or "our") is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Our products include surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling, emergency medical equipment and intensive care disposable products; clinical communication and artificial intelligence-assisted virtual care platform technology; neurosurgical and neurovascular devices; implants used in joint replacement and trauma surgeries; Mako Robotic-Arm Assisted technology; spinal devices; as well as other products used in a variety of medical specialties.During the fourth quarter 2024 we changed the name of our “Orthopaedics and Spine” operating segment to “Orthopaedics.”
Basis of Presentation and Consolidation The Consolidated Financial Statements include the Company and its subsidiaries. All significant intercompany accounts and transactions are eliminated in consolidation. We have no material interests in variable interest entities. Certain prior year amounts have been reclassified to conform with current year presentation in our Consolidated Financial Statements.
Our reportable segments and related disclosures reflect certain reclassifications of prior year amounts from our Orthopaedics segment to our MedSurg and Neurotechnology segment due to changes in our internal reporting structure.
Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities on the date of the financial statements and the reported amounts of net sales and expenses in the reporting period. Actual results could differ from those estimates.
Revenue Recognition Sales are recognized as the performance obligations to deliver products or services (including services under extended warranty service contracts) are satisfied and are recorded based on the amount of consideration we expect to receive in exchange for satisfying the performance obligations. Our sales are recognized primarily when we transfer control to the customer, which can be on the date of shipment, the date of receipt by the customer or, for most Orthopaedics products, when we have received a purchase order and appropriate notification the product has been used or implanted. Products and services are primarily transferred to customers at a point in time, with some transfers of services taking place over time.
Sales represent the amount of consideration we expect to receive from customers in exchange for transferring products and services. Net sales exclude sales, value added and other taxes we collect from customers. Other costs to obtain and fulfill contracts are generally expensed as incurred due to the short-term nature of most of our sales. We extend terms of payment to our customers based on commercially reasonable terms for the markets of our customers, while also considering their credit quality.
A provision for estimated sales returns, discounts and rebates is recognized as a reduction of sales in the same period that the sales are recognized. Our estimate of the provision for sales
returns has been established based on contract terms with our customers and historical business practices and current trends. Shipping and handling costs charged to customers are included in net sales.
Cost of Sales Cost of sales include direct materials and supplies consumed in the manufacture of product, as well as manufacturing labor, depreciation expense and direct overhead expense necessary to acquire and convert the purchased materials and supplies into finished product. Cost of sales also includes the cost to distribute products to customers, inbound freight costs, warehousing costs and other shipping and handling activity.
Research, Development and Engineering Expenses Research, development and engineering costs are charged to expense as incurred and include research, development and engineering activities relating to the development of new products, improvement of existing products, technical support of products and compliance with governmental regulations for the protection of customers and patients. Costs primarily include salaries, wages, consulting and depreciation and maintenance of research facilities and equipment.
Selling, General and Administrative Expenses include selling expenses, marketing expenses, administrative and other indirect overhead costs, amortization of loaner instrumentation, depreciation and amortization expense of non-manufacturing assets and other miscellaneous operating items.
Currency Translation Financial statements of subsidiaries outside the United States generally are measured using the local currency as the functional currency. Adjustments to translate those statements into United States Dollars are recorded in other comprehensive income (OCI). Transactional exchange gains and losses are included in other income (expense), net.
Cash Equivalents Highly liquid investments with remaining stated maturities of three months or less when purchased or other money market instruments that are redeemable upon demand are considered cash equivalents and recorded at cost.
Short-term Investments Short-term investments that have a maturity greater than three months and less than a year from the date of purchase primarily include time deposits, certificates of deposit, commercial paper, bonds and notes, substantially all of which are denominated in United States Dollars and are stated at cost plus accrued interest, which approximates fair value. We expect to hold all of our short-term investments to maturity.
Marketable Securities Marketable securities include marketable debt securities and mutual funds. Mutual funds are acquired to offset changes in certain liabilities related to deferred compensation arrangements and are expected to be used to settle these liabilities and are recognized in other noncurrent assets. Pursuant to our investment policy, all individual marketable security investments must have a minimum credit quality of single A (Standard & Poor’s and Fitch) and A2 (Moody’s Corporation) at the time of acquisition, while the overall portfolio of marketable securities must maintain a minimum average credit quality of double A (Standard & Poor’s and Fitch) or Aa (Moody’s Corporation). In the event of a rating downgrade below the minimum credit quality subsequent to purchase, the marketable security investment is evaluated to determine the appropriate action to take to minimize the overall risk to our marketable security investment portfolio. Our marketable securities are classified as available-for-sale and trading securities. Investments in trading securities represent participant-directed investments of deferred employee compensation.
Accounts Receivable Accounts receivable include trade and other miscellaneous receivables. An allowance is maintained for doubtful accounts for estimated losses in the collection of accounts receivable. Estimates are made regarding the ability of customers to make required payments based on historical credit experience, current market conditions and expected credit losses. Accounts receivable are written off when all reasonable collection efforts are exhausted.
Inventories Inventories are stated at the lower of cost or net realizable value, with cost generally determined using the first-in, first-out (FIFO) cost method. For excess and obsolete inventory resulting from the potential inability to sell specific products at prices in excess of current carrying costs, reserves are maintained to reduce current carrying cost to net realizable value.
Financial Instruments Our financial instruments include cash, cash equivalents, marketable securities, accounts receivable, other investments, accounts payable, debt and foreign currency exchange contracts. The carrying value of our financial instruments, with the exception of our senior unsecured notes, approximates fair value on December 31, 2024 and 2023. Refer to Notes 3 and 10 for further details.
All marketable securities are recognized at fair value. Adjustments to the fair value of marketable securities that are classified as available-for-sale are recognized as increases or decreases, net of income taxes, within accumulated other comprehensive income (AOCI) in shareholders’ equity and adjustments to the fair value of marketable securities that are classified as trading are recognized in earnings. The amortized cost of marketable debt securities is adjusted for amortization of premiums and discounts to maturity computed under the effective interest method. Such amortization and interest and realized gains and losses are included in other income (expense), net. The cost of securities sold is determined by the specific identification method.
We review declines in the fair value of our investments classified as available-for-sale to determine whether the decline in fair value is a result of credit loss or other factors. Impairments of available-for-sale marketable debt securities related to credit loss are included in earnings and impairments related to other factors are recognized within AOCI.
Derivatives All derivatives are recognized at fair value and reported on a gross basis. We enter into forward currency exchange contracts to mitigate the impact of currency fluctuations on transactions denominated in nonfunctional currencies, thereby limiting our risk that would otherwise result from changes in exchange rates. The periods of the forward currency exchange contracts correspond to the periods of the exposed transactions, with realized gains and losses included in the measurement and recording of transactions denominated in the nonfunctional currencies. All forward currency exchange contracts are recorded at their fair value each period.
Forward currency exchange contracts designated as cash flow hedges are designed to hedge the variability of cash flows associated with forecasted transactions denominated in a foreign currency that will take place in the future. These nonfunctional currency exposures principally relate to forecasted intercompany sales and purchases of manufactured products and generally have maturities up to eighteen months. Changes in value of derivatives designated as cash flow hedges are recorded in AOCI on the Consolidated Balance Sheets until earnings are affected by the variability of the underlying cash flows. At that time, the applicable amount of gain or loss from the derivative instrument that is deferred in shareholders’ equity is reclassified into
earnings and is included in cost of goods sold. Cash flows associated with these hedges are included in cash provided by operating activities in the same category as the cash flows from the items being hedged.
Forward currency exchange contracts are used to offset our exposure to the change in value of specific foreign currency denominated assets and liabilities, primarily intercompany payables and receivables. These derivatives are not designated as hedges and, therefore, changes in the value of these forward contracts are recognized in earnings, thereby offsetting the current earnings effect of the related changes in value of foreign currency denominated assets and liabilities. The estimated fair value of our forward currency exchange contracts represents the measurement of the contracts at month-end spot rates as adjusted by current forward points.
From time to time, we designate derivative and non-derivative financial instruments as net investment hedges of our investments in certain international subsidiaries. For derivative instruments that are designated and qualify as a net investment hedge, the effective portion of the derivative's gain or loss is recognized in OCI and reported as a component of AOCI. We have elected to use the spot method to assess effectiveness for our derivatives designated as net investment hedges. Accordingly, the change in fair value attributable to changes in the spot rate is recorded in AOCI. We exclude the spot-forward difference from the assessment of hedge effectiveness and amortize this amount separately on a straight-line basis over the term of the forward contracts. This amortization is recognized in other income (expense), net.
From time to time, we designate forward starting interest rate derivative instruments as cash flow hedges to manage the exposure to interest rate volatility with regard to future issuance and refinancing of debt. Changes in value of derivatives designated as cash flow hedges are recorded in AOCI until earnings are affected by the variability of the underlying cash flows. At that time, the applicable amount of gain or loss from the derivative instrument that is deferred in shareholders’ equity is reclassified into earnings and is included in interest expense within other income (expense), net.
Interest rate derivative instruments designated as fair value hedges have been used in the past to manage the exposure to interest rate movements and to reduce borrowing costs by converting fixed-rate debt into floating-rate debt. Under these agreements, we agree to exchange, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount.
Property, Plant and Equipment Property, plant and equipment is stated at cost. Depreciation is generally computed by the straight-line method over the estimated useful lives of three to 30 years for buildings and improvements and three to 15 years for machinery and equipment.
Goodwill and Other Intangible Assets Goodwill represents the excess of purchase price over fair value of tangible net assets of acquired businesses at the acquisition date, after amounts allocated to other identifiable intangible assets. Factors that contribute to the recognition of goodwill include synergies that are specific to our business and not available to other market participants and are expected to increase net sales and profits; acquisition of a talented workforce; cost savings opportunities; the strategic benefit of expanding our presence in core and adjacent markets; and diversifying our product portfolio.
The fair values of other identifiable intangible assets acquired in a business combination are primarily determined using the income
approach. Other intangible assets include, but are not limited to, developed technology, customer and distributor relationships (which reflect expected continued customer or distributor patronage) and trademarks and patents. Intangible assets with determinable useful lives are amortized on a straight-line basis over their estimated useful lives of four to 40 years. Certain acquired trade names are considered to have indefinite lives and are not amortized, but are assessed annually for potential impairment as described below.
In some of our acquisitions, we acquire in-process research and development (IPRD) intangible assets. For acquisitions accounted for as business combinations IPRD is considered to be an indefinite-lived intangible asset until the research is completed (then it becomes a determinable-lived intangible asset) or determined to have no future use (then it is impaired). For asset acquisitions IPRD is expensed immediately unless there is an alternative future use.
Goodwill, Intangibles and Long-Lived Asset Impairment Tests We perform our annual impairment test for goodwill as of October 31 each year. We consider qualitative indicators of the fair value of a reporting unit when it is unlikely that a reporting unit has impaired goodwill and periodically corroborate that assessment with quantitative information. In certain circumstances, we may also utilize a discounted cash flow analysis that requires certain assumptions and estimates be made regarding market conditions and our future profitability. Indefinite-lived intangible assets are also tested at least annually for impairment by comparing the individual carrying values to the fair value.
We review long-lived assets for indicators of impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. The evaluation is performed at the lowest level of identifiable cash flows. Undiscounted cash flows expected to be generated by the related assets are estimated over the asset's useful life based on updated projections. If the evaluation indicates that the carrying amount of the asset may not be recoverable, any potential impairment is measured based upon the fair value of the related asset or asset group as determined by an appropriate market appraisal or other valuation technique.
Assets And Liabilities Held For Sale We classify assets and liabilities or disposal groups to be sold as held for sale in the period in which all of the following criteria are met: management, having the authority to approve the action, commits to a plan to sell the disposal group; the disposal group is available for immediate sale in its present condition subject only to terms that are usual and customary for sales of such disposal groups; an active program to locate a buyer and other actions required to complete the plan to sell the disposal group have been initiated; the sale of the disposal group is probable, and transfer of the disposal group is expected to qualify for recognition as a completed sale within one year, except if events or circumstances beyond our control extend the period of time required to sell the disposal group beyond one year; the disposal group is being actively marketed for sale at a price that is reasonable in relation to its current fair value; and actions required to complete the plan indicate that it is unlikely that significant changes to the plan will be made or that the plan will be withdrawn.
We initially measure a disposal group that is classified as held for sale at the lower of its carrying value or fair value less any costs to sell. Any loss resulting from this measurement is recognized in the period in which the held for sale criteria are met. Conversely, gains are not recognized on the sale of a disposal group until the sale is completed. We assess the fair value of a disposal group, less any costs to sell, each reporting period it remains classified as held for sale and report any subsequent changes as an adjustment to the carrying value of the disposal group, as long as the new carrying value does not exceed the carrying value of the disposal group at the time it was initially classified as held for sale.
Upon determining that a disposal group meets the criteria to be classified as held for sale, we cease depreciation and amortization of the assets and disclose the major classes of assets and liabilities of the disposal group in the Notes to the Consolidated Financial Statements. Refer to Note 16 for further information.
Share-Based Compensation hare-based compensation is in the form of stock options, restricted stock units (RSUs) and performance stock units (PSUs). Stock options are granted under long-term incentive plans to certain key employees and non-employee directors at an exercise price not less than the fair market value of the underlying common stock, which is the quoted closing price of our common stock on the day prior to the date of grant. The options are granted for periods of up to 10 years and become exercisable in varying installments.
We grant RSUs to key employees and non-employee directors and PSUs to certain key employees under our long-term incentive plans. The fair value of RSUs is determined based on the number of shares granted and the quoted closing price of our common stock on the date of grant, adjusted for the fact that RSUs do not include anticipated dividends. RSUs generally vest in one-third increments over a three-year period and are settled in stock. PSUs are earned over a three-year performance cycle and vest in March of the year following the end of that performance cycle. The number of PSUs that will ultimately be earned is based on our performance relative to pre-established goals in that three-year performance cycle. The fair value of PSUs is determined based on the quoted closing price of our common stock on the day of grant.
Compensation expense is recognized in the Consolidated Statements of Earnings based on the estimated fair value of the awards on the grant date. Compensation expense recognized reflects an estimate of the number of awards expected to vest after taking into consideration an estimate of award forfeitures based on actual experience and is recognized on a straight-line basis over the requisite service period, which is generally the period required to obtain full vesting. Management expectations related to the achievement of performance goals associated with PSU grants is assessed regularly and that assessment is used to determine whether PSU grants are expected to vest. If performance-based milestones related to PSU grants are not met or not expected to be met, any compensation expense recognized associated with such grants will be reversed.
Income Taxes Deferred income tax assets and liabilities are determined based on differences between financial reporting and income tax bases of assets and liabilities and are measured using the enacted income tax rates in effect for the years in which the differences are expected to reverse. Deferred income tax benefits generally represent the change in net deferred income tax assets and liabilities in the year. Other amounts result from
adjustments related to acquisitions and foreign currency as appropriate.
We operate in multiple income tax jurisdictions both within the United States and internationally. Accordingly, management must determine the appropriate allocation of income to each of these jurisdictions based on current interpretations of complex income tax regulations. Income tax authorities in these jurisdictions regularly perform audits of our income tax filings. Income tax audits associated with the allocation of this income and other complex issues, including inventory transfer pricing and cost sharing, product royalty and foreign branch arrangements, may require an extended period of time to resolve and may result in significant income tax adjustments if changes to the income allocation are required between jurisdictions with different income tax rates.
The Tax Cuts and Jobs Act (the Act) was enacted in 2017 in the United States. The Act also subjects a United States shareholder to tax on Global Intangible Low-Taxed Income (GILTI) earned by certain foreign subsidiaries. We have elected to account for GILTI tax in the year the tax is incurred.
New Accounting Pronouncements Not Yet Adopted and Accounting Pronouncements Recently Adopted
New Accounting Pronouncements Not Yet Adopted
In November 2024 the Financial Accounting Standards Board (FASB) issued ASU 2024-03 (Subtopic 220-40): Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures which requires disaggregation of certain expense captions into specified categories in disclosures within the Notes to the Consolidated Financial Statements. The new disclosure requirements are effective for fiscal years beginning after December 15, 2026 and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. We are currently evaluating these new expanded disclosure requirements.
In December 2023 the FASB issued ASU 2023-09 (Topic 740): Income Taxes: Improvements to Income Tax Disclosures which expands the existing rules on income tax disclosures. This update requires entities to disclose specific categories in the tax rate reconciliation, provide additional information for reconciling items that meet a quantitative threshold and disclose additional information about income taxes paid on an annual basis. The new disclosure requirements are effective for fiscal years beginning after December 15, 2024. Early adoption is permitted. We are currently evaluating these new expanded disclosure requirements.
Accounting Pronouncements Recently Adopted
On January 1, 2024 we adopted ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. Refer to Note 14 for further information.
On January 1, 2023 we adopted ASU 2022-04, Liabilities - Supplier Finance Programs: Disclosure of Supplier Finance Program Obligations. Refer to Note 7 for required disclosures.
v3.25.0.1
Revenue Recognition (Tables)
 12 Months Ended
Dec. 31, 2024
Revenue Recognition [Abstract]  
Schedule of Disaggregated Revenue
Segment Net Sales
MedSurg and Neurotechnology:202420232022
Instruments$2,834 $2,534 $2,245 
Endoscopy3,389 3,068 2,759 
Medical3,852 3,459 3,031 
Neurovascular1,307 1,226 1,200 
Neuro Cranial2,136 1,876 1,658 
$13,518 $12,163 $10,893 
Orthopaedics:
Knees$2,447 $2,273 $1,997 
Hips1,704 1,544 1,413 
Trauma and Extremities3,507 3,147 2,807 
Spinal Implants707 713 733 
Other712 658 606 
$9,077 $8,335 $7,556 
Total$22,595 $20,498 $18,449 
United States Net Sales
MedSurg and Neurotechnology:202420232022
Instruments$2,267 $2,016 $1,776 
Endoscopy2,792 2,513 2,245 
Medical3,191 2,785 2,422 
Neurovascular506 483 446 
Neuro Cranial1,761 1,531 1,359 
$10,517 $9,328 $8,248 
Orthopaedics:
Knees$1,788 $1,676 $1,493 
Hips1,059 988 896 
Trauma and Extremities2,586 2,297 2,035 
Spinal Implants489 500 511 
Other504 468 455 
$6,426 $5,929 $5,390 
Total$16,943 $15,257 $13,638 
International Net Sales
MedSurg and Neurotechnology:202420232022
Instruments$567 $518 $469 
Endoscopy597 555 514 
Medical661 674 609 
Neurovascular801 743 754 
Neuro Cranial375 345 299 
$3,001 $2,835 $2,645 
Orthopaedics:
Knees$659 $597 $504 
Hips645 556 517 
Trauma and Extremities921 850 772 
Spinal Implants218 213 222 
Other208 190 151 
$2,651 $2,406 $2,166 
Total$5,652 $5,241 $4,811 
Changes in Contract Liabilities Changes in contract liabilities during the year were as follows:
2024
Beginning contract liabilities$860 
Revenue recognized from beginning of year contract liabilities(553)
Net advance consideration received during the period671 
Ending contract liabilities$978 
v3.25.0.1
Fair Value Measurements (Tables)
 12 Months Ended
Dec. 31, 2024
Fair Value Disclosures [Abstract]  
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis
Assets Measured at Fair Value
20242023
Cash and cash equivalents$3,652 $2,971 
Short-term investments750 — 
Trading marketable securities259 209 
Level 1 - Assets$4,661 $3,180 
Available-for-sale marketable securities:
Corporate and asset-backed debt securities$53 $43 
United States agency debt securities1 4 
United States treasury debt securities34 31 
Certificates of deposit3 4 
Total available-for-sale marketable securities$91 $82 
Foreign currency exchange forward contracts225 116 
Level 2 - Assets$316 $198 
Total assets measured at fair value$4,977 $3,378 
Liabilities Measured at Fair Value
20242023
Deferred compensation arrangements$259 $209 
Level 1 - Liabilities$259 $209 
Foreign currency exchange forward contracts$77 $97 
Level 2 - Liabilities$77 $97 
Contingent consideration:
Beginning$289 $121 
Additions208 192 
Change in estimate and foreign exchange8 (2)
Settlements(53)(22)
Ending$452 $289 
Level 3 - Liabilities$452 $289 
Total liabilities measured at fair value$788 $595 
Available-for-sale Securities
Fair Value of Available for Sale Securities by Maturity
20242023
Due in one year or less$47 $46 
Due after one year through three years$44 $36 
v3.25.0.1
Derivative Instruments (Tables)
 12 Months Ended
Dec. 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value
2024Cash FlowNet InvestmentNon-DesignatedTotal
Gross notional amount$1,588 $2,338 $5,164 $9,090 
Maximum term in years9.7
Fair value:
Other current assets$43 $24 $119 $186 
Other noncurrent assets4 35 — 39 
Other current liabilities(29)— (41)(70)
Other noncurrent liabilities(3)(4)— (7)
Total fair value$15 $55 $78 $148 
2023Cash FlowNet InvestmentNon-DesignatedTotal
Gross notional amount$1,650 $1,662 $4,315 $7,627 
Maximum term in years2.9
Fair value:
Other current assets$24 $74 $16 $114 
Other noncurrent assets2 — — 2 
Other current liabilities(16)— (36)(52)
Other noncurrent liabilities(2)(43)— (45)
Total fair value$8 $31 $(20)$19 
Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location
Currency Exchange Rate Gains (Losses) Recognized in Net Earnings
Derivative InstrumentRecognized in:202420232022
Cash FlowCost of sales$31 $39 $23 
Net InvestmentOther income (expense), net35 34 39 
Non-DesignatedOther income (expense), net40 25 30 
Total$106 $98 $92 
v3.25.0.1
Accumulated Other Comprehensive (Loss) Income (AOCI) (Tables)
 12 Months Ended
Dec. 31, 2024
Reclassification Adjustments Out of Accumulated Other Comprehensive Income (AOCI) [Abstract]  
Schedule of Accumulated Other Comprehensive Income (Loss)
Marketable SecuritiesPension PlansHedgesFinancial Statement TranslationTotal
2022$(1)$31 $52 $(303)$(221)
OCI1 (67)27 (157)(196)
Income taxes— 12 (5)59 66 
Reclassifications to:
Cost of sales— — (39)— (39)
Other (income) expense, net— (5)(5)(34)(44)
Income taxes— 1 9 8 18 
Net OCI$1 $(59)$(13)$(124)$(195)
2023$— $(28)$39 $(427)$(416)
OCI— 43 26 236 305 
Income taxes— (11)(7)(110)(128)
Reclassifications to:
Cost of sales— — (31)— (31)
Other (income) expense, net— — (4)(35)(39)
Income taxes— — 8 8 16 
Net OCI$— $32 $(8)$99 $123 
2024$— $4 $31 $(328)$(293)
v3.25.0.1
Acquisitions (Tables)
 12 Months Ended
Dec. 31, 2024
Business Combinations [Abstract]  
Allocation Of The Preliminary Purchase Price To The Acquired Net Assets Of Acquisitions
The purchase price allocations for the acquisitions completed in 2024 and Cerus are:
Purchase Price Allocation of Acquired Net Assets
20242023
TotalCerus
Tangible assets acquired:
Accounts receivable$46 $1 
Inventory112 2 
Deferred income tax assets28 4 
Other assets27 1 
Debt(42)— 
Deferred income tax liabilities(205)(60)
Other liabilities(102)(22)
Intangible assets:
Developed technologies596 240 
Customer relationships214 — 
Patents6 — 
Trademarks2 — 
Goodwill1,154 315 
Purchase price, net of cash acquired of $57 and $7
$1,836 $481 
Weighted-average amortization period at acquisition (years):
Developed technologies1213
Customer relationships14— 
Patents12— 
Trademarks5— 
v3.25.0.1
Contingencies and Commitments (Tables)
 12 Months Ended
Dec. 31, 2024
Commitments and Contingencies Disclosure [Abstract]  
Lease, Cost
20242023
Right-of-use assets $516 $494 
Lease liabilities, current $144 $143 
Lease liabilities, noncurrent $379 $356 
Other information:
Weighted-average remaining lease term (years)5.15.5
Weighted-average discount rate3.87 %3.87 %
Future Purchase Obligations and Minimum Lease Payments
20252026202720282029Thereafter
Debt repayments$1,410 $1,000 $779 $1,823 $1,581 $7,109 
Purchase obligations$2,610 $157 $43 $16 $14 $15 
Minimum lease payments$156 $126 $91 $61 $43 $73 
Supplier Finance Program
2024
Beginning confirmed obligations$51 
Additions392 
Settlements(372)
Ending confirmed obligations$71 
v3.25.0.1
Goodwill and Other Intangible Assets (Tables)
 12 Months Ended
Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Changes in the Net Carrying Amount of Goodwill by Segment
Changes in the Net Carrying Value of Goodwill by Segment
MedSurg and NeurotechnologyOrthopaedicsTotal
2022$7,935 $6,945 $14,880 
Additions and adjustments301 — 301 
Foreign exchange and other34 28 62 
2023$8,270 $6,973 $15,243 
Goodwill impairment— (456)(456)
Additions and adjustments852 300 1,152 
Foreign exchange and other86 (170)(84)
2024$9,208 $6,647 $15,855 
Summary of the Company's Other Intangible Assets
Summary of Other Intangible Assets
Gross
Carrying
Amount		Less
Accumulated
Amortization		Net
Carrying
Amount
Developed technologies
2024$5,698 $2,931 $2,767 
20235,769 2,815 2,954 
Customer relationships
2024$3,055 $1,636 $1,419 
20232,907 1,504 1,403 
Patents
2024$153 $136 $17 
2023329 302 27 
Trademarks
2024$413 $256 $157 
2023427 246 181 
In-process research and development
2024$34 $— $34 
202321 — 21 
Other
2024$63 $62 $1 
202396 89 7 
Total
2024$9,416 $5,021 $4,395 
20239,549 4,956 4,593 
Estimated Amortization Expense
Estimated Amortization Expense
20252026202720282029
$605 $550 $528 $480 $465 
v3.25.0.1
Capital Stock (Tables)
 12 Months Ended
Dec. 31, 2024
Capital Stock [Abstract]  
Schedule of Fair Value Assumptions
Option Value and Assumptions
202420232022
Weighted-average fair value per share$118.22 $83.59 $68.08 
Assumptions:
Risk-free interest rate4.3 %4.0 %1.8 %
Expected dividend yield1.1 %1.2 %1.0 %
Expected stock price volatility29.9 %29.0 %27.0 %
Expected option life (years)6.36.25.9
Summary of Stock Option Activity
2024 Stock Option Activity
Shares
(in millions)		Weighted-Average
Exercise Price		Weighted-Average
Remaining
Term (in years)		Aggregate
Intrinsic
 Value
Outstanding January 111.5 $189.70 
Granted1.3 339.72 
Exercised(1.7)134.86 
Canceled or forfeited(0.3)274.74 
Outstanding December 3110.8 $214.87 5.3$1,572.6 
Exercisable December 316.6 $175.39 3.1$1,223.3 
Options expected to vest3.9 $275.67 7.7$331.8 
Summary of RSU and PSU Activity
Restricted Stock Units (RSUs) and Performance Stock Units (PSUs) Activity
Shares
(in millions)		Weighted-Average
Grant Date Fair Value
RSUsPSUsRSUsPSUs
Nonvested on January 10.7 0.2 $246.98 $250.17 
Granted0.3 0.1 332.64 305.99 
Vested(0.3)(0.1)244.18 233.95 
Canceled or forfeited— — 276.23 233.95 
Nonvested on December 310.7 0.2 $290.58 $287.51 
v3.25.0.1
Debt and Credit Facilities (Tables)
 12 Months Ended
Dec. 31, 2024
Long-Term Debt, Unclassified [Abstract]  
Maturities Of Long-Term Debt Disclosures
Summary of Total Debt
RateDue20242023
Senior unsecured notes:
3.375%May 15, 2024$— $600 
VariousNovember 16, 2024— 554 
0.250%December 3, 2024— 940 
1.150%June 15, 2025649 648 
3.375%November 1, 2025750 749 
3.500%March 15, 2026998 997 
2.125%November 30, 2027777 828 
3.650%March 7, 2028598 598 
4.850%December 8, 2028596 596 
3.375%December 11, 2028621 661 
0.750%March 1, 2029828 883 
4.250%September 11, 2029743 — 
1.950%June 15, 2030993 991 
2.625%November 30, 2030669 713 
1.000%December 3, 2031772 823 
3.375%September 11, 2032824 — 
4.625%September 11, 2034740 — 
3.625%September 11, 2036613 — 
4.100%April 1, 2043393 393 
4.375%May 15, 2044396 396 
4.625%March 15, 2046984 983 
2.900%June 15, 2050643 642 
Other10 — 
Total debt$13,597 $12,995 
Less current maturities1,409 2,094 
Total long-term debt$12,188 $10,901 
Unamortized debt issuance costs$63 $50 
Borrowing capacity on existing facilities$2,160 $2,160 
Fair value of senior unsecured notes$12,780 $12,252 
v3.25.0.1
Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2024
Income Tax Disclosure [Abstract]  
Schedule of Reconciliation of U.S. Statutory Income Tax Rate to Company's Effective Income Tax Rate from Continuing Operations
Effective Income Tax Rate Reconciliation
202420232022
United States federal statutory rate21.0 %21.0 %21.0 %
United States state and local income taxes, less federal deduction1.1 1.1 2.0 
Foreign income tax at rates other than 21%(4.1)(6.8)(4.1)
Tax related to repatriation of foreign earnings0.3 1.2 (2.4)
United States research and development credits(1.4)(1.2)(1.5)
Intellectual property transfers— (3.3)0.1 
United States federal audit settlement— — (6.1)
Goodwill impairment2.8 — 1.7 
Outside basis difference related to the anticipated sale of the Spinal Implants business(4.9)— — 
Other(0.5)1.8 1.4 
Effective income tax rate14.3 %013.8 %12.1 %
Schedule of Provision for Income Taxes
Earnings Before Income Taxes 
202420232022
United States$523 $701 $407 
International2,969 2,972 2,276 
Total$3,492 $3,673 $2,683 
Components of Income Tax Expense (Benefit)
Current income tax expense (benefit):202420232022
United States federal$490 $236 $(76)
United States state and local90 48 64 
International289 430 279 
Total current income tax expense$869 $714 $267 
Deferred income tax expense (benefit):
United States federal$(462)$(212)$(179)
United States state and local(76)(20)(30)
International168 26 267 
Total deferred income tax expense (benefit)$(370)$(206)$58 
Total income tax expense$499 $508 $325 
Schedule of Difference in Income Tax Effects Comprising Company's Deferred Income Tax Assets and Liabilities
Deferred Income Tax Assets and Liabilities
Deferred income tax assets:20242023
Inventories$551 $521 
Other accrued expenses207 253 
Depreciation and amortization715 918 
State income taxes167 150 
Share-based compensation100 86 
Research and development capitalization408 295 
International interest expense carryforwards52 46 
Net operating loss and credit carryforwards410 385 
Outside basis difference related to the anticipated sale of the Spinal Implants business170 — 
Other310 235 
Total deferred income tax assets$3,090 $2,889 
Less valuation allowances(228)(223)
Net deferred income tax assets$2,862 $2,666 
Deferred income tax liabilities:
Depreciation and amortization$(1,141)$(1,012)
Undistributed earnings(61)(47)
Total deferred income tax liabilities$(1,202)$(1,059)
Net deferred income tax assets$1,660 $1,607 
Reported as:
Noncurrent deferred income tax assets$1,742 $1,670 
Noncurrent liabilities—Other liabilities(82)(63)
Total$1,660 $1,607 
Schedule of Unrecognized Tax Benefits Roll Forward
Uncertain Income Tax Positions
 20242023
Beginning uncertain tax positions$371 $286 
Increases related to current year income tax positions18 102 
Increases related to prior year income tax positions— 10 
Decreases related to prior year income tax positions(4)(33)
Settlements of income tax audits(21)(1)
Statute of limitations expirations and other(3)— 
Foreign currency translation(12)7 
Ending uncertain tax positions$349 $371 
Reported as:
Noncurrent liabilities—Income taxes$349 $371 
v3.25.0.1
Retirement Plans (Tables)
 12 Months Ended
Dec. 31, 2024
Retirement Benefits [Abstract]  
Defined Contribution Plan Disclosures
202420232022
Plan expense$376 $327 $305 
Expense funded with Stryker common stock62 57 41 
Stryker common stock held by plan:
Dollar amount$781 $649 $522 
Shares (in millions)2.2 2.2 2.1 
Value as a percentage of total plan assets10 %10 %10 %
Schedule of Costs of Retirement Plans
Components of Net Periodic Pension Cost
Net periodic benefit cost:202420232022
Service cost$(39)$(32)$(56)
Interest cost(21)(23)(10)
Expected return on plan assets19 18 15 
Amortization of prior service credit1 1 1 
Recognized actuarial gain (loss)(1)4 (9)
Net periodic benefit cost$(41)$(32)$(59)
Changes in assets and benefit obligations recognized in OCI:
Net actuarial gain (loss)$43 $(67)$244 
Recognized net actuarial (gain) loss1 (4)9 
Prior service credit and transition amount(1)(1)(1)
Total recognized in other comprehensive income (loss)$43 $(72)$252 
Total recognized in net periodic benefit cost and OCI$2 $(104)$193 
Weighted-average rates used to determine net periodic benefit cost:
Discount rate2.8 %3.3 %1.1 %
Expected return on plan assets4.3 %4.2 %3.1 %
Rate of compensation increase3.0 %3.0 %2.6 %
Weighted-average discount rate used to determine projected benefit obligations2.9 %2.8 %3.3 %
Schedule of Defined Benefit Plans Disclosures
20242023
Fair value of plan assets$492 $485 
Benefit obligations(782)(826)
Funded status$(290)$(341)
Reported as:
Noncurrent assets—other assets$48 $21 
Current liabilities—accrued compensation(3)(3)
Noncurrent liabilities—other liabilities(335)(359)
Pre-tax amounts recognized in AOCI:
Unrecognized net actuarial gain (loss)6 (39)
Unrecognized prior service credit8 11 
Total$14 $(28)
Schedule of Changes in Accumulated Postemployment Benefit Obligations
Change in Benefit Obligations
20242023
Beginning projected benefit obligations$826 $673 
Service cost39 32 
Interest cost21 23 
Foreign exchange impact(52)32 
Employee contributions7 7 
Actuarial (gains) losses(40)79 
Benefits paid(19)(20)
Ending projected benefit obligations$782 $826 
Ending accumulated benefit obligations$748 $790 
Schedule of Changes in Fair Value of Plan Assets
Change in Plan Assets
20242023
Beginning fair value of plan assets$485 $420 
Actual return22 29 
Employer contributions23 23 
Employee contributions7 7 
Foreign exchange impact(31)22 
Benefits paid(14)(16)
Ending fair value of plan assets$492 $485 
Valuation of Plan Assets
2024Level 1Level 2Level 3Total
Cash and cash equivalents$17 $— $— $17 
Equity securities8 125 — 133 
Debt securities2 203 — 205 
Other4 76 57 137 
Total$31 $404 $57 $492 
2023Level 1Level 2Level 3Total
Cash and cash equivalents$15 $— $— $15 
Equity securities20 130 — 150 
Debt securities2 185 — 187 
Other5 63 65 133 
Total$42 $378 $65 $485 
Schedule of Allocation of Plan Assets
Allocation of Plan Assets
2025 Target2024 Actual2023 Actual
Equity securities24 %28 %28 %
Debt securities44 40 37 
Other32 32 35 
Total100 %100 %100 %
Schedule of Expected Benefit Payments
Estimated Future Benefit Payments
202520262027202820292030-2034
$24 $23 $25 $26 $27 $171 
v3.25.0.1
Summary of Quarterly Data (Unaudited) (Tables)
 12 Months Ended
Dec. 31, 2024
Quarterly Financial Data [Abstract]  
Summary of Quarterly Data
2024 QuartersMar 31Jun 30Sep 30Dec 31
Net sales$5,243 $5,422 $5,494 $6,436 
Gross profit3,333 3,416 3,517 4,174 
Earnings before income taxes923 998 1,043 528 
Net earnings788 825 834 546 
Net earnings per share of common stock:
Basic$2.07 $2.17 $2.18 $1.43 
Diluted$2.05 $2.14 $2.16 $1.41 
Dividends declared per share of common stock$0.80 $0.80 $0.80 $0.84 
2023 QuartersMar 31Jun 30Sep 30Dec 31
Net sales$4,778 $4,996 $4,909 $5,815 
Gross profit3,016 3,181 3,158 3,703 
Earnings before income taxes679 899 869 1,226 
Net earnings592 738 692 1,143 
Net earnings per share of common stock:
Basic$1.56 $1.95 $1.82 $3.01 
Diluted$1.54 $1.93 $1.80 $2.98 
Dividends declared per share of common stock$0.75 $0.75 $0.75 $0.80 
v3.25.0.1
Segment and Geographic Data (Tables)
 12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
Reconciliation of Operating Profit (Loss) from Segments to Consolidated
Segment Results202420232022
MedSurg and Neurotechnology$13,518 $12,163 $10,893 
Orthopaedics$9,077 8,335 7,556 
Net sales$22,595 $20,498 $18,449 
MedSurg and Neurotechnology$5,320 $4,876 $4,637 
Orthopaedics$2,400 2,254 1,920 
Cost of sales $7,720 $7,130 $6,557 
MedSurg and Neurotechnology$784 $702 $682 
Orthopaedics$540 508 477 
Segment research, development and engineering expenses$1,324 $1,210 $1,159 
MedSurg and Neurotechnology$3,203 $2,934 $2,564 
Orthopaedics$3,111 2,922 2,608 
Segment selling, general and administrative expenses $6,314 $5,856 $5,172 
MedSurg and Neurotechnology$208 $181 $178 
Orthopaedics433 386 350 
Segment depreciation and amortization $641 $567 $528 
Corporate and Other162 139 123 
Amortization of intangible assets623 635 627 
Total depreciation and amortization$1,426 $1,341 $1,278 
MedSurg and Neurotechnology$4,004 $3,470 $2,831 
Orthopaedics2,591 2,265 2,202 
Segment operating income$6,595 $5,735 $5,033 
Items not allocated to segments:
Corporate and Other$(880)$(780)$(649)
Inventory stepped up to fair value(46)— — 
Acquisition and integration-related charges(108)(20)(138)
Amortization of intangible assets(623)(635)(627)
Structural optimization and other special charges(138)(170)(295)
Goodwill and other impairments(977)(36)(270)
Medical device regulation(58)(96)(140)
Recall-related matters(40)(18)15 
Regulatory and legal matters(36)(92)(76)
Consolidated operating income$3,689 $3,888 $2,841 
Sales and Other Financial Information by Business Segment
Segment Assets and Capital Spending
Assets:20242023
MedSurg and Neurotechnology$23,115 $20,804 
Orthopaedics18,507 18,023 
Total segment assets$41,622 $38,827 
Corporate and Other1,349 1,085 
Total assets$42,971 $39,912 
Purchases of property, plant and equipment:202420232022
Orthopaedics$230 $179 $173 
MedSurg and Neurotechnology276 183 175 
Total segment purchases of property, plant and equipment$506 $362 $348 
Corporate and Other249 213 240 
Total purchases of property, plant and equipment$755 $575 $588 
Geographic Information on Net Sales and Long-Lived Assets
Geographic Information
Net SalesNet Property, Plant and Equipment
20242023202220242023
United States$16,943 $15,257 $13,638 $1,997 $1,874 
Europe, Middle East, Africa2,897 2,618 2,348 1,260 1,151 
Asia Pacific2,020 1,946 1,885 75 77 
Other countries735 677 578 116 113 
Total$22,595 $20,498 $18,449 $3,448 $3,215 
v3.25.0.1
Assets Held for Sale (Tables)
 12 Months Ended
Dec. 31, 2024
Discontinued Operations and Disposal Groups [Abstract]  
Disposal Groups, Including Discontinued Operations The assets and liabilities held for sale are classified within prepaid expenses and other current assets and accrued expenses and other liabilities in our Consolidated Balance Sheets and included the following as of December 31, 2024:
2024
Accounts receivable, net$62 
Total inventories 183
Prepaid expenses and other current assets 10
Property, plant and equipment, net 51
Other intangibles, net 326
Noncurrent deferred income tax assets 9
Other noncurrent assets 171
Valuation allowance (362)
Total assets held for sale $450 
Accounts payable $28 
Accrued compensation 26
Accrued expenses and other liabilities 29
Other noncurrent liabilities 21
Total liabilities held for sale$104 
v3.25.0.1
Significant Accounting Policies (Details)
 12 Months Ended
Dec. 31, 2024
Derivative term (up to) 18 months
Employee Stock Option  
Expiration period 10 years
Restricted Stock Units (RSUs)  
Vesting period 3 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage 33.33%
Performance Stock Units (PSUs)  
Performance period 3 years
Minimum  
Finite-lived intangible asset, useful life 4 years
Maximum  
Finite-lived intangible asset, useful life 40 years
Building and Improvements | Minimum  
Property, plant and equipment useful life 3 years
Building and Improvements | Maximum  
Property, plant and equipment useful life 30 years
Machinery and Equipment | Minimum  
Property, plant and equipment useful life 3 years
Machinery and Equipment | Maximum  
Property, plant and equipment useful life 15 years
v3.25.0.1
Revenue Recognition - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Dec. 31, 2024
Sep. 30, 2024
Jun. 30, 2024
Mar. 31, 2024
Dec. 31, 2023
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Disaggregation of Revenue [Line Items]                      
Percentage of sales recognized as services over time (less than)                 10.00%    
Net sales $ 6,436 $ 5,494 $ 5,422 $ 5,243 $ 5,815 $ 4,909 $ 4,996 $ 4,778 $ 22,595 $ 20,498 $ 18,449
Contract liabilities $ 978       $ 860       978 860  
Neuro Cranial - Interventional Spine                      
Disaggregation of Revenue [Line Items]                      
Net sales                 413 327 282
Other Orthopedics - Enabling Technologies                      
Disaggregation of Revenue [Line Items]                      
Net sales                 $ 152 $ 149 $ 131
v3.25.0.1
Revenue Recognition - Disaggregated Sales Analysis (Details) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Dec. 31, 2024
Sep. 30, 2024
Jun. 30, 2024
Mar. 31, 2024
Dec. 31, 2023
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Disaggregation of Revenue [Line Items]                      
Net sales $ 6,436 $ 5,494 $ 5,422 $ 5,243 $ 5,815 $ 4,909 $ 4,996 $ 4,778 $ 22,595 $ 20,498 $ 18,449
United States                      
Disaggregation of Revenue [Line Items]                      
Net sales                 16,943 15,257 13,638
International                      
Disaggregation of Revenue [Line Items]                      
Net sales                 5,652 5,241 4,811
MedSurg and Neurotechnology                      
Disaggregation of Revenue [Line Items]                      
Net sales                 13,518 12,163 10,893
MedSurg and Neurotechnology | United States                      
Disaggregation of Revenue [Line Items]                      
Net sales                 10,517 9,328 8,248
MedSurg and Neurotechnology | International                      
Disaggregation of Revenue [Line Items]                      
Net sales                 3,001 2,835 2,645
MedSurg and Neurotechnology | Instruments                      
Disaggregation of Revenue [Line Items]                      
Net sales                 2,834 2,534 2,245
MedSurg and Neurotechnology | Instruments | United States                      
Disaggregation of Revenue [Line Items]                      
Net sales                 2,267 2,016 1,776
MedSurg and Neurotechnology | Instruments | International                      
Disaggregation of Revenue [Line Items]                      
Net sales                 567 518 469
MedSurg and Neurotechnology | Endoscopy                      
Disaggregation of Revenue [Line Items]                      
Net sales                 3,389 3,068 2,759
MedSurg and Neurotechnology | Endoscopy | United States                      
Disaggregation of Revenue [Line Items]                      
Net sales                 2,792 2,513 2,245
MedSurg and Neurotechnology | Endoscopy | International                      
Disaggregation of Revenue [Line Items]                      
Net sales                 597 555 514
MedSurg and Neurotechnology | Medical                      
Disaggregation of Revenue [Line Items]                      
Net sales                 3,852 3,459 3,031
MedSurg and Neurotechnology | Medical | United States                      
Disaggregation of Revenue [Line Items]                      
Net sales                 3,191 2,785 2,422
MedSurg and Neurotechnology | Medical | International                      
Disaggregation of Revenue [Line Items]                      
Net sales                 661 674 609
MedSurg and Neurotechnology | Neurovascular                      
Disaggregation of Revenue [Line Items]                      
Net sales                 1,307 1,226 1,200
MedSurg and Neurotechnology | Neurovascular | United States                      
Disaggregation of Revenue [Line Items]                      
Net sales                 506 483 446
MedSurg and Neurotechnology | Neurovascular | International                      
Disaggregation of Revenue [Line Items]                      
Net sales                 801 743 754
MedSurg and Neurotechnology | Neuro Cranial                      
Disaggregation of Revenue [Line Items]                      
Net sales                 2,136 1,876 1,658
MedSurg and Neurotechnology | Neuro Cranial | United States                      
Disaggregation of Revenue [Line Items]                      
Net sales                 1,761 1,531 1,359
MedSurg and Neurotechnology | Neuro Cranial | International                      
Disaggregation of Revenue [Line Items]                      
Net sales                 375 345 299
Orthopaedics                      
Disaggregation of Revenue [Line Items]                      
Net sales                 9,077 8,335 7,556
Orthopaedics | United States                      
Disaggregation of Revenue [Line Items]                      
Net sales                 6,426 5,929 5,390
Orthopaedics | International                      
Disaggregation of Revenue [Line Items]                      
Net sales                 2,651 2,406 2,166
Orthopaedics | Other                      
Disaggregation of Revenue [Line Items]                      
Net sales                 712 658 606
Orthopaedics | Other | United States                      
Disaggregation of Revenue [Line Items]                      
Net sales                 504 468 455
Orthopaedics | Other | International                      
Disaggregation of Revenue [Line Items]                      
Net sales                 208 190 151
Orthopaedics | Knees                      
Disaggregation of Revenue [Line Items]                      
Net sales                 2,447 2,273 1,997
Orthopaedics | Knees | United States                      
Disaggregation of Revenue [Line Items]                      
Net sales                 1,788 1,676 1,493
Orthopaedics | Knees | International                      
Disaggregation of Revenue [Line Items]                      
Net sales                 659 597 504
Orthopaedics | Hips                      
Disaggregation of Revenue [Line Items]                      
Net sales                 1,704 1,544 1,413
Orthopaedics | Hips | United States                      
Disaggregation of Revenue [Line Items]                      
Net sales                 1,059 988 896
Orthopaedics | Hips | International                      
Disaggregation of Revenue [Line Items]                      
Net sales                 645 556 517
Orthopaedics | Trauma and Extremities                      
Disaggregation of Revenue [Line Items]                      
Net sales                 3,507 3,147 2,807
Orthopaedics | Trauma and Extremities | United States                      
Disaggregation of Revenue [Line Items]                      
Net sales                 2,586 2,297 2,035
Orthopaedics | Trauma and Extremities | International                      
Disaggregation of Revenue [Line Items]                      
Net sales                 921 850 772
Orthopaedics | Spine                      
Disaggregation of Revenue [Line Items]                      
Net sales                 707 713 733
Orthopaedics | Spine | United States                      
Disaggregation of Revenue [Line Items]                      
Net sales                 489 500 511
Orthopaedics | Spine | International                      
Disaggregation of Revenue [Line Items]                      
Net sales                 $ 218 $ 213 $ 222
v3.25.0.1
Revenue Recognition - Changes in Contract Liabilities (Details)
$ in Millions
 12 Months Ended
Dec. 31, 2024
USD ($)
Movement In Contract Liabilities [Roll Forward]  
Beginning contract liabilities $ 860
Revenue recognized from beginning of year contract liabilities (553)
Net advance consideration received during the period 671
Ending contract liabilities $ 978
v3.25.0.1
Fair Value Measurements (Valuation Of Financial Instruments By Pricing Categories) (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Assets    
Available-for-sale marketable securities: $ 91 $ 82
Total assets measured at fair value 4,977 3,378
Contingent Consideration Arrangements, Change in Amount of Contingent Consideration [Abstract]    
Total liabilities measured at fair value 788 595
(Level 1)    
Assets    
Available-for-sale marketable securities 3,652 2,971
Short-term investments 750 0
Trading marketable securities 259 209
Total assets measured at fair value 4,661 3,180
Liabilities:    
Deferred compensation arrangements 259 209
Contingent Consideration Arrangements, Change in Amount of Contingent Consideration [Abstract]    
Total liabilities measured at fair value 259 209
(Level 2)    
Assets    
Available-for-sale marketable securities: 91 82
Total assets measured at fair value 316 198
Contingent Consideration Arrangements, Change in Amount of Contingent Consideration [Abstract]    
Total liabilities measured at fair value 77 97
(Level 2) | Corporate and asset-backed debt securities    
Assets    
Available-for-sale marketable securities: 53 43
(Level 2) | United States agency debt securities    
Assets    
Available-for-sale marketable securities: 1 4
(Level 2) | United States treasury debt securities    
Assets    
Available-for-sale marketable securities: 34 31
(Level 2) | Certificates of deposit    
Assets    
Available-for-sale marketable securities: 3 4
(Level 2) | Foreign currency exchange forward contracts    
Assets    
Foreign currency exchange forward contracts 225 116
Interest rate swap asset 225 116
Liabilities:    
Foreign currency exchange forward contracts 77 97
(Level 3)    
Contingent Consideration Arrangements, Change in Amount of Contingent Consideration [Abstract]    
Beginning 289 121
Additions 208 192
Change in estimate and foreign exchange 8 (2)
Settlements (53) (22)
Ending 452 289
Total liabilities measured at fair value $ 452 $ 289
v3.25.0.1
Fair Value Measurements (Available-For-Sale Securities) (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Fair Value Disclosures [Abstract]    
Due in one year or less $ 47 $ 46
Due after one year through three years $ 44 $ 36
v3.25.0.1
Fair Value Measurements (Narrative) (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Jun. 30, 2024
May 02, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Reduction of contingent consideration   $ 208      
Interest income $ 139 $ 75 $ 25    
Cerus          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Fair value of contingent consideration       $ 192 $ 192
v3.25.0.1
Derivative Instruments (Forward Currency Exchange Contracts) (Details) - Foreign currency exchange forward contracts
$ in Millions, € in Billions
 12 Months Ended
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2024
EUR (€)
Dec. 31, 2023
EUR (€)
Derivative [Line Items]        
Notional amount $ 9,090 $ 7,627    
Maximum term 9 years 8 months 12 days 2 years 10 months 24 days    
Derivative, fair value, net $ 148 $ 19    
Other current assets        
Derivative [Line Items]        
Derivative asset 186 114    
Other noncurrent assets        
Derivative [Line Items]        
Derivative asset 39 2    
Other current liabilities        
Derivative [Line Items]        
Derivative liability (70) (52)    
Other noncurrent liabilities        
Derivative [Line Items]        
Derivative liability (7) (45)    
Designated as Hedging Instrument | Other noncurrent liabilities        
Derivative [Line Items]        
Derivative liability   (43)    
Not Designated as Hedging Instrument        
Derivative [Line Items]        
Notional amount 5,164 4,315    
Derivative, fair value, net 78 (20)    
Not Designated as Hedging Instrument | Other current assets        
Derivative [Line Items]        
Derivative asset 119 16    
Not Designated as Hedging Instrument | Other noncurrent assets        
Derivative [Line Items]        
Derivative asset 0 0    
Not Designated as Hedging Instrument | Other current liabilities        
Derivative [Line Items]        
Derivative liability (41) (36)    
Not Designated as Hedging Instrument | Other noncurrent liabilities        
Derivative [Line Items]        
Derivative liability 0 0    
Cash Flow Hedging | Designated as Hedging Instrument        
Derivative [Line Items]        
Notional amount 1,588 1,650    
Derivative, fair value, net 15 8    
Cash Flow Hedging | Designated as Hedging Instrument | Other current assets        
Derivative [Line Items]        
Derivative asset 43 24    
Cash Flow Hedging | Designated as Hedging Instrument | Other noncurrent assets        
Derivative [Line Items]        
Derivative asset 4 2    
Cash Flow Hedging | Designated as Hedging Instrument | Other current liabilities        
Derivative [Line Items]        
Derivative liability (29) (16)    
Cash Flow Hedging | Designated as Hedging Instrument | Other noncurrent liabilities        
Derivative [Line Items]        
Derivative liability (3) (2)    
Net Investment Hedging | Designated as Hedging Instrument        
Derivative [Line Items]        
Notional amount 2,338 1,662 € 2.3 € 1.5
Derivative, fair value, net 55 31    
Net Investment Hedging | Designated as Hedging Instrument | Other current assets        
Derivative [Line Items]        
Derivative asset 24 74    
Net Investment Hedging | Designated as Hedging Instrument | Other noncurrent assets        
Derivative [Line Items]        
Derivative asset 35 0    
Net Investment Hedging | Designated as Hedging Instrument | Other current liabilities        
Derivative [Line Items]        
Derivative liability 0 $ 0    
Net Investment Hedging | Designated as Hedging Instrument | Other noncurrent liabilities        
Derivative [Line Items]        
Derivative liability $ (4)      
v3.25.0.1
Derivative Instruments (Narrative) (Details)
$ in Millions, € in Billions
 12 Months Ended
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2024
EUR (€)
Dec. 31, 2023
EUR (€)
Derivative Instruments, Gain (Loss) [Line Items]          
Derivative term (up to) 18 months        
Proceeds from settlement of net investment hedges $ 99 $ 0 $ 197    
Foreign currency exchange forward contracts          
Derivative Instruments, Gain (Loss) [Line Items]          
Derivative, notional amount $ 9,090 7,627      
Derivative term (up to) 9 years 8 months 12 days        
Designated as Hedging Instrument | Foreign currency exchange forward contracts          
Derivative Instruments, Gain (Loss) [Line Items]          
After-tax gain (loss) recognized in AOCI related to designated net investment hedges $ 325        
Cash flow hedge gain (loss) to be reclassified within twelve months 14        
Net investment hedges expected to be reclassified to cost of sales and other income (expense) 43        
Designated as Hedging Instrument | Foreign currency exchange forward contracts | Net Investment Hedging          
Derivative Instruments, Gain (Loss) [Line Items]          
Derivative, notional amount 2,338 $ 1,662   € 2.3 € 1.5
Designated as Hedging Instrument | Interest rate swap          
Derivative Instruments, Gain (Loss) [Line Items]          
Cash flow hedge gain (loss) to be reclassified within twelve months $ 4        
Designated as Hedging Instrument | Embedded Derivative Financial Instruments | Net Investment Hedging          
Derivative Instruments, Gain (Loss) [Line Items]          
Derivative, notional amount | €       € 5.0 € 4.9
v3.25.0.1
Derivative Instruments (Movements out of OCI) (Details) - Foreign currency exchange forward contracts - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Derivative [Line Items]      
Foreign currency transaction gains (losses) $ 106 $ 98 $ 92
Cost of sales      
Derivative [Line Items]      
Foreign currency transaction gains (losses) 31 39 23
Designated as Hedging Instrument      
Derivative [Line Items]      
Derivatives used in Net Investment Hedge, Gain (Loss), Reclassified to Earnings, Net of Tax 43    
Designated as Hedging Instrument | Other income (expense), net      
Derivative [Line Items]      
Foreign currency transaction gains (losses) 35 34 39
Not Designated as Hedging Instrument | Other income (expense), net      
Derivative [Line Items]      
Foreign currency transaction gains (losses) $ 40 $ 25 $ 30
v3.25.0.1
Accumulated Other Comprehensive (Loss) Income (AOCI) (Schedule of Amounts Recognized in Other Comprehensive Income (Loss)) (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]      
Accumulated Other Comprehensive Income (Loss), Beginning of Period $ (416) $ (221)  
OCI 305 (196)  
Income taxes (128) 66  
Cost of sales 8,155 7,440 $ 6,871
Other (income) expense, net (197) (215) (158)
Income taxes 499 508 325
Other comprehensive income (loss) 123 (195) 310
Accumulated Other Comprehensive Income (Loss), End of Period (293) (416) (221)
Reclassification out of Accumulated Other Comprehensive Income      
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]      
Cost of sales (31) (39)  
Other (income) expense, net (39) (44)  
Income taxes 16 18  
Other comprehensive income (loss) 123 (195)  
Marketable Securities      
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]      
Accumulated Other Comprehensive Income (Loss), Beginning of Period 0 (1)  
OCI 0 1  
Income taxes 0 0  
Accumulated Other Comprehensive Income (Loss), End of Period 0 0 (1)
Marketable Securities | Reclassification out of Accumulated Other Comprehensive Income      
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]      
Cost of sales 0 0  
Other (income) expense, net 0 0  
Income taxes 0 0  
Other comprehensive income (loss) 0 1  
Pension Plans      
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]      
Accumulated Other Comprehensive Income (Loss), Beginning of Period (28) 31  
OCI 43 (67)  
Income taxes (11) 12  
Accumulated Other Comprehensive Income (Loss), End of Period 4 (28) 31
Pension Plans | Reclassification out of Accumulated Other Comprehensive Income      
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]      
Cost of sales 0 0  
Other (income) expense, net 0 (5)  
Income taxes 0 1  
Other comprehensive income (loss) 32 (59)  
Hedges      
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]      
Accumulated Other Comprehensive Income (Loss), Beginning of Period 39 52  
OCI 26 27  
Income taxes (7) (5)  
Accumulated Other Comprehensive Income (Loss), End of Period 31 39 52
Hedges | Reclassification out of Accumulated Other Comprehensive Income      
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]      
Cost of sales (31) (39)  
Other (income) expense, net (4) (5)  
Income taxes 8 9  
Other comprehensive income (loss) (8) (13)  
Financial Statement Translation      
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]      
Accumulated Other Comprehensive Income (Loss), Beginning of Period (427) (303)  
OCI 236 (157)  
Income taxes (110) 59  
Accumulated Other Comprehensive Income (Loss), End of Period (328) (427) $ (303)
Financial Statement Translation | Reclassification out of Accumulated Other Comprehensive Income      
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]      
Cost of sales 0 0  
Other (income) expense, net (35) (34)  
Income taxes 8 8  
Other comprehensive income (loss) $ 99 $ (124)  
v3.25.0.1
Acquisitions (Narrative) (Details) - USD ($)
$ in Millions
 12 Months Ended
May 02, 2023
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Jun. 30, 2024
Business Acquisition [Line Items]          
Cash paid for acquisitions, net of cash acquired   $ 1,628 $ 390 $ 2,563  
Various          
Business Acquisition [Line Items]          
Cash paid for acquisitions, net of cash acquired   1,628      
Future milestone payout   400      
Fair value of contingent consideration   $ 208      
Cerus          
Business Acquisition [Line Items]          
Fair value of contingent consideration $ 192       $ 192
Aggregate purchase price of acquisitions 289        
Business acquisition, future milestone payments (up to) $ 225        
v3.25.0.1
Acquisitions (Allocation Of The Preliminary Purchase Price To The Acquired Net Assets Of Acquisitions) (Details) - USD ($)
$ in Millions
 12 Months Ended
May 02, 2023
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Business Acquisition [Line Items]        
Goodwill   $ 15,855 $ 15,243 $ 14,880
Various        
Business Acquisition [Line Items]        
Accounts receivable   46    
Deferred income tax assets   28    
Inventory   112    
Other assets   27    
Debt   (42)    
Deferred income tax liabilities   (205)    
Other liabilities   (102)    
Goodwill   1,154    
Purchase price, net of cash acquired of $57 and $7   1,836    
Cash Acquired from Acquisition   57    
Various | Customer relationships        
Business Acquisition [Line Items]        
Intangible assets:   214    
Various | Developed technologies        
Business Acquisition [Line Items]        
Intangible assets:   $ 596    
Weighted-average amortization period at acquisition (years):   12 years    
Various | Trademarks        
Business Acquisition [Line Items]        
Intangible assets:   $ 2    
Various | Customer Relationships [Member]        
Business Acquisition [Line Items]        
Weighted-average amortization period at acquisition (years):   14 years    
Various | Trademarks        
Business Acquisition [Line Items]        
Weighted-average amortization period at acquisition (years):   5 years    
Various | Patents        
Business Acquisition [Line Items]        
Weighted-average amortization period at acquisition (years):   12 years    
Various | Patents        
Business Acquisition [Line Items]        
Intangible assets:   $ 6    
Cerus        
Business Acquisition [Line Items]        
Accounts receivable $ 1      
Deferred income tax assets 4      
Inventory 2      
Other assets 1      
Debt 0      
Deferred income tax liabilities (60)      
Other liabilities (22)      
Goodwill 315      
Purchase price, net of cash acquired of $57 and $7 481      
Cash Acquired from Acquisition 7      
Cerus | Customer relationships        
Business Acquisition [Line Items]        
Intangible assets: 0      
Cerus | Developed technologies        
Business Acquisition [Line Items]        
Intangible assets: $ 240      
Weighted-average amortization period at acquisition (years): 13 years      
Cerus | Trademarks        
Business Acquisition [Line Items]        
Intangible assets: $ 0      
Cerus | Patents        
Business Acquisition [Line Items]        
Intangible assets: $ 0      
v3.25.0.1
Contingencies and Commitments (Narrative) (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Loss Contingencies [Line Items]      
Lease expense $ 190 $ 172 $ 149
Supplier finance obligation $ 71 $ 51  
Supplier Finance Program, Obligation, Current, Statement of Financial Position [Extensible Enumeration] Accounts Payable, Trade, Current Accounts Payable, Trade, Current  
Recall Matters      
Loss Contingencies [Line Items]      
Charges during period $ 17    
Estimate of possible loss $ 202    
v3.25.0.1
Commitments and Contingencies (Lease Cost) (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]    
Right-of-use assets $ 516 $ 494
Lease liabilities, current 144 143
Lease liabilities, noncurrent $ 379 $ 356
Weighted-average remaining lease term (years) 5 years 1 month 6 days 5 years 6 months
Weighted-average discount rate 3.87% 3.87%
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Other Assets, Noncurrent Other Assets, Noncurrent
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List] Other Liabilities, Current Other Liabilities, Current
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] Other noncurrent liabilities Other noncurrent liabilities
v3.25.0.1
Contingencies and Commitments (Future Purchase Obligations and Minimum Lease Payments) (Details)
$ in Millions
Dec. 31, 2024
USD ($)
Commitments and Contingencies Disclosure [Abstract]  
2025 $ 1,410
2026 1,000
2027 779
2028 1,823
2029 1,581
Thereafter 7,109
Purchase obligations  
2025 2,610
2026 157
2027 43
2028 16
2029 14
Thereafter 15
Minimum lease payments  
2025 156
2026 126
2027 91
2028 61
2029 43
Thereafter $ 73
v3.25.0.1
Contingencies and Commitments (Supplier Finance Program) (Details)
$ in Millions
 12 Months Ended
Dec. 31, 2024
USD ($)
Supplier Finance Program, Obligation [Roll Forward]  
Beginning confirmed obligations $ 51
Additions 392
Settlements (372)
Ending confirmed obligations $ 71
Supplier Finance Program, Obligation, Statement of Financial Position [Extensible Enumeration] Accounts Payable, Trade, Current
v3.25.0.1
Goodwill and Other Intangible Assets (Goodwill) (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Goodwill [Line Items]    
Goodwill, impairment loss $ 456  
Goodwill [Roll Forward]    
Goodwill, Beginning balance 15,243 $ 14,880
Additions and adjustments 1,152 301
Foreign exchange and other (84) 62
Goodwill impairment (456)  
Goodwill, Ending balance 15,855 15,243
MedSurg and Neurotechnology    
Goodwill [Line Items]    
Goodwill, impairment loss 0  
Goodwill [Roll Forward]    
Goodwill, Beginning balance 8,270 7,935
Additions and adjustments 852 301
Foreign exchange and other 86 34
Goodwill impairment 0  
Goodwill, Ending balance 9,208 8,270
Orthopaedics    
Goodwill [Line Items]    
Goodwill, impairment loss 456  
Goodwill [Roll Forward]    
Goodwill, Beginning balance 6,973 6,945
Additions and adjustments 300 0
Foreign exchange and other (170) 28
Goodwill impairment (456)  
Goodwill, Ending balance 6,647 $ 6,973
Spinal Implants | Disposal Group, Held-for-Sale, Not Discontinued Operations    
Goodwill [Line Items]    
Goodwill, impairment loss 183  
Goodwill [Roll Forward]    
Goodwill impairment (183)  
Spine Reporting Unit    
Goodwill [Line Items]    
Goodwill, impairment loss 273  
Goodwill [Roll Forward]    
Goodwill impairment (273)  
MedSurg and Neurotechnology    
Goodwill [Line Items]    
Goodwill transfer 117  
Orthopaedics    
Goodwill [Line Items]    
Goodwill transfer $ (117)  
v3.25.0.1
Goodwill and Other Intangible Assets (Summary of the Company's Other Intangible Assets) (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Acquired Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount $ 9,416 $ 9,549
Less Accumulated Amortization 5,021 4,956
Net Carrying Amount 4,395 4,593
Developed technologies    
Acquired Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount 5,698 5,769
Less Accumulated Amortization 2,931 2,815
Net Carrying Amount 2,767 2,954
Customer relationships    
Acquired Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount 3,055 2,907
Less Accumulated Amortization 1,636 1,504
Net Carrying Amount 1,419 1,403
Patents    
Acquired Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount 153 329
Less Accumulated Amortization 136 302
Net Carrying Amount 17 27
Trademarks    
Acquired Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount 413 427
Less Accumulated Amortization 256 246
Net Carrying Amount 157 181
In-process research and development    
Acquired Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount 34 21
Less Accumulated Amortization 0 0
Net Carrying Amount 34 21
Other    
Acquired Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount 63 96
Less Accumulated Amortization 62 89
Net Carrying Amount $ 1 $ 7
v3.25.0.1
Goodwill and Other Intangible Assets (Estimated Amortization Expense) (Details)
$ in Millions
Dec. 31, 2024
USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]  
2025 $ 605
2026 550
2027 528
2028 480
2029 $ 465
v3.25.0.1
Capital Stock (Narrative) (Details) - USD ($)
$ / shares in Units, $ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Capital Stock [Line Items]      
Common and Preferred Stock, shares authorized (in shares) 1,000,500,000    
Preferred stock, shares authorized 500,000    
Preferred stock, par per share $ 1    
Common stock, authorized (in shares) 1,000,000,000    
Common stock, par value (in dollars per share) $ 0.10 $ 0.10  
Preferred stock, outstanding (in shares) 0    
Remaining shares authorized to be repurchased $ 1,033    
Capital shares reserved for future issuance 18,000,000 20,000,000  
Aggregate intrinsic value of options exercised $ 362 $ 318 $ 218
Options exercised during period, exercise price range, lower range limit $ 92.24    
Options exercised during period, exercise price range, upper range limit $ 339.77    
Compensation cost not yet recognized $ 159    
Compensation cost not yet recognized, period for recognized 1 year 6 months    
Restricted Stock Units (RSUs)      
Capital Stock [Line Items]      
Compensation cost not yet recognized $ 90    
Compensation cost not yet recognized, period for recognized 1 year    
Weighted average grant date fair value, Granted (in dollars per share) $ 332.64 $ 257.09  
Shares vested during the period $ 81    
Performance Stock Units (PSUs)      
Capital Stock [Line Items]      
Compensation cost not yet recognized $ 23    
Compensation cost not yet recognized, period for recognized 1 year    
Weighted average grant date fair value, Granted (in dollars per share) $ 305.99    
Shares vested during the period $ 23    
Employee Stock Purchase Plans      
Capital Stock [Line Items]      
Percentage of closing stock price under ESPP 95.00%    
Shares issued under the ESPP 173,708 190,524  
v3.25.0.1
Capital Stock (Option Grant Assumptions) (Details) - $ / shares
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Capital Stock [Abstract]      
Weighted-average fair value per share $ 118.22 $ 83.59 $ 68.08
Risk-free interest rate 4.30% 4.00% 1.80%
Expected dividend yield 1.10% 1.20% 1.00%
Expected stock price volatility 29.90% 29.00% 27.00%
Expected option life (years) 6 years 3 months 18 days 6 years 2 months 12 days 5 years 10 months 24 days
v3.25.0.1
Capital Stock (Summary of Stock Option Activity) (Details)
$ / shares in Units, shares in Millions, $ in Millions
 12 Months Ended
Dec. 31, 2024
USD ($)
$ / shares
shares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]  
Shares, Options outstanding at January 1 (in shares) | shares 11.5
Shares, Granted (in shares) | shares 1.3
Shares, Exercised (in shares) | shares (1.7)
Shares, Cancelled or forfeited (in shares) | shares (0.3)
Shares, Options outstanding at December 31 (in shares) | shares 10.8
Shares, Exercisable at December 31 (in shares) | shares 6.6
Shares, Options expected to vest (in shares) | shares 3.9
Weighted-Average Exercise Price  
Weighted average exercise price, Options outstanding at January 1 (in dollars per share) | $ / shares $ 189.70
Weighted average exercise price, Granted (in dollars per share) | $ / shares 339.72
Weighted average exercise price, Exercised (in dollars per share) | $ / shares 134.86
Weighted average exercise price, Cancelled or forfeited (in dollars per share) | $ / shares 274.74
Weighted average exercise price, Options outstanding at December 31 (in dollars per share) | $ / shares 214.87
Weighted average exercise price, Exercisable at December 31 (in dollars per share) | $ / shares 175.39
Weighted average exercise price, Options expected to vest (in dollars per share) | $ / shares $ 275.67
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]  
Weighted-average remaining contractual term, Options outstanding (in years) 5 years 3 months 18 days
Weighted-average remaining contractual term, Exercisable (in years) 3 years 1 month 6 days
Weighted-average remaining contractual term, Options expected to vest (in years) 7 years 8 months 12 days
Aggregate intrinsic value, Options outstanding | $ $ 1,572.6
Aggregate intrinsic value, Exercisable | $ 1,223.3
Aggregate intrinsic value, Options expected to vest | $ $ 331.8
v3.25.0.1
Capital Stock (Summary of RSU and PSU Activity) (Details) - $ / shares
shares in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Restricted Stock Units (RSUs)    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]    
Shares, Nonvested at January 1 (in shares) 0.7  
Shares, Granted (in shares) 0.3  
Shares, Vested (in shares) (0.3)  
Shares, Cancelled (in shares) 0.0  
Shares, Nonvested at December 31 (in shares) 0.7 0.7
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]    
Weighted average grant date fair value, Outstanding at January 1 (in dollars per share) $ 246.98  
Weighted average grant date fair value, Granted (in dollars per share) 332.64 $ 257.09
Weighted average grant date fair value, Vested (in dollars per share) 244.18  
Weighted average grant date fair value, Cancelled (in dollars per share) 276.23  
Weighted average grant date fair value, Outstanding at December 31 (in dollars per share) $ 290.58 $ 246.98
Performance Stock Units (PSUs)    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]    
Shares, Nonvested at January 1 (in shares) 0.2  
Shares, Granted (in shares) 0.1  
Shares, Vested (in shares) (0.1)  
Shares, Cancelled (in shares) 0.0  
Shares, Nonvested at December 31 (in shares) 0.2 0.2
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]    
Weighted average grant date fair value, Outstanding at January 1 (in dollars per share) $ 250.17  
Weighted average grant date fair value, Granted (in dollars per share) 305.99  
Weighted average grant date fair value, Vested (in dollars per share) 233.95  
Weighted average grant date fair value, Cancelled (in dollars per share) 233.95  
Weighted average grant date fair value, Outstanding at December 31 (in dollars per share) $ 287.51 $ 250.17
v3.25.0.1
Debt and Credit Facilities (Narrative) (Details)
€ in Millions
 1 Months Ended 12 Months Ended
May 31, 2024
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2024
EUR (€)
Line of Credit Facility [Line Items]          
Commercial paper   $ 0      
Credit facility outstanding amount   0      
Interest expense, debt   $ 396,000,000 $ 356,000,000 $ 337,000,000  
Floating Rate Senior Notes Due November 16, 2024          
Line of Credit Facility [Line Items]          
Repayments of debt $ 500,000,000        
Senior Unsecured Notes 4.850% Due 2028          
Line of Credit Facility [Line Items]          
Stated interest rate   4.85%     4.85%
Senior Unsecured Notes, 3.375% Due 2028          
Line of Credit Facility [Line Items]          
Stated interest rate   3.375%     3.375%
Senior Unsecured Notes, 4.250% Due 2029          
Line of Credit Facility [Line Items]          
Debt face amount   $ 750,000,000      
Stated interest rate   4.25%     4.25%
Senior Unsecured Notes 0.250% due 2024          
Line of Credit Facility [Line Items]          
Repayments of debt $ 850,000,000        
Stated interest rate 0.25%   0.25%    
Senior Unsecured Notes 3.375% due 2024          
Line of Credit Facility [Line Items]          
Repayments of debt $ 600,000,000        
Stated interest rate 3.375% 3.375%     3.375%
Senior Unsecured Notes 3.375% due 2025          
Line of Credit Facility [Line Items]          
Debt face amount | €         € 800
Stated interest rate   3.375%     3.375%
Senior Unsecured Notes 4.625% due 2046          
Line of Credit Facility [Line Items]          
Debt face amount   $ 750,000,000      
Stated interest rate   4.625%     4.625%
3.625% Notes due 2036          
Line of Credit Facility [Line Items]          
Debt face amount | €         € 600
Stated interest rate   3.625%     3.625%
Commercial Paper          
Line of Credit Facility [Line Items]          
Debt term   397 days      
Debt face amount   $ 2,250,000,000      
v3.25.0.1
Debt and Credit Facilities (Maturities Of Long-Term Debt Disclosures) (Details) - USD ($)
$ in Millions
Dec. 31, 2024
May 31, 2024
Dec. 31, 2023
Other long-term debt $ 10   $ 0
Total debt 13,597   12,995
Current maturities of debt 1,409   2,094
Total long-term debt 12,188   10,901
Unamortized debt issuance costs 63   50
Borrowing capacity on existing facilities 2,160   2,160
Fair value of senior unsecured notes $ 12,780   12,252
Senior Unsecured Notes 3.375% due 2024      
Stated interest rate 3.375% 3.375%  
Unsecured debt $ 0   600
Various      
Unsecured debt 0   $ 554
Senior Unsecured Notes 0.250% due 2024      
Stated interest rate   0.25% 0.25%
Unsecured debt $ 0   $ 940
Senior Unsecured Notes, 1.150% Due 2025      
Stated interest rate 1.15%    
Unsecured debt $ 649   648
Senior Unsecured Notes 3.375% due 2025      
Stated interest rate 3.375%    
Unsecured debt $ 750   749
Senior Unsecured Notes 3.500% due 2026      
Stated interest rate 3.50%    
Unsecured debt $ 998   997
Senior Unsecured Notes, Due November 2027      
Stated interest rate 2.125%    
Unsecured debt $ 777   828
Senior Unsecured Notes 3.650% due 2028      
Stated interest rate 3.65%    
Unsecured debt $ 598   598
Senior Unsecured Notes 4.850% Due 2028      
Stated interest rate 4.85%    
Unsecured debt $ 596   596
Senior Unsecured Notes, 3.375% Due 2028      
Stated interest rate 3.375%    
Unsecured debt $ 621   661
Senior Unsecured Notes 0.750% due 2029      
Stated interest rate 0.75%    
Unsecured debt $ 828   883
Senior Unsecured Notes, 4.250% Due 2029      
Stated interest rate 4.25%    
Unsecured debt $ 743   0
Senior Unsecured Notes, 1.950% Due 2030      
Stated interest rate 1.95%    
Unsecured debt $ 993   991
2.625% Notes due 2030      
Stated interest rate 2.625%    
Unsecured debt $ 669   713
Senior Unsecured Notes 1.000% due 2031      
Stated interest rate 1.00%    
Unsecured debt $ 772   823
3.375% Notes due 2032      
Stated interest rate 3.375%    
Unsecured debt $ 824   0
Senior Unsecured Notes 4.625% due September 11, 2034      
Stated interest rate 4.625%    
Unsecured debt $ 740   0
3.625% Notes due 2036      
Stated interest rate 3.625%    
Unsecured debt $ 613   0
Senior Unsecured Notes 4.100% due 2043      
Stated interest rate 4.10%    
Unsecured debt $ 393   393
Senior Unsecured Notes 4.375% due 2044      
Stated interest rate 4.375%    
Unsecured debt $ 396   396
Senior Unsecured Notes 4.625% due 2046      
Stated interest rate 4.625%    
Unsecured debt $ 984   983
Senior Unsecured Notes, 2.900% due 2050      
Stated interest rate 2.90%    
Unsecured debt $ 643   $ 642
v3.25.0.1
Income Taxes (Narrative) (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Income Tax Contingency [Line Items]      
Effective income tax, percent 14.30% 13.80% 12.10%
Unrecognized tax benefits, income tax penalties and interest expense $ 13 $ 1 $ 71
Net operating loss carryforward recognized 9 189 56
Accrued interest and penalties 71 67  
Tax credit carryforward, amount 204    
Tax credit carryforward, valuation allowance   83  
Repatriation of foreign earnings reversed     $ 71
Undistributed earnings of foreign subsidiaries 10,000    
Unrecognized tax benefits, interest on income tax expense 224 $ 248  
Tax settlement amount 162    
Tax settlement, release of accrued interest (50)    
Federal      
Income Tax Contingency [Line Items]      
Operating loss carryforwards 335    
Deferred tax assets, operating loss carryforwards 70    
Operating loss carryforwards, subject to full valuation allowance 2    
State      
Income Tax Contingency [Line Items]      
Operating loss carryforwards 3,480    
Deferred tax assets, operating loss carryforwards 85    
Operating loss carryforwards, subject to full valuation allowance 49    
International      
Income Tax Contingency [Line Items]      
Operating loss carryforwards 269    
Deferred tax assets, operating loss carryforwards 69    
Operating loss carryforwards, subject to full valuation allowance $ 63    
v3.25.0.1
Income Taxes (Schedule of Reconciliation of U.S. Statutory Income Tax Rate to Company's Effective Income Tax Rate from Continuing Operations) (Details)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Income Tax Disclosure [Abstract]      
United States federal statutory rate 21.00% 21.00% 21.00%
United States state and local income taxes, less federal deduction 1.10% 1.10% 2.00%
Foreign income tax at rates other than 21% (4.10%) (6.80%) (4.10%)
Tax related to repatriation of foreign earnings 0.30% 1.20% (2.40%)
United States research and development credits (1.40%) (1.20%) (1.50%)
Intellectual property transfers 0.00% (3.30%) 0.10%
United States federal audit settlement 0.00% 0.00% (6.10%)
Goodwill impairment 2.80% 0.00% 1.70%
Outside basis difference related to the anticipated sale of the Spinal Implants business (4.90%) 0.00% 0.00%
Other (0.50%) 1.80% 1.40%
Effective income tax rate 14.30% 13.80% 12.10%
v3.25.0.1
Income Taxes (Schedule of Earnings before Income Taxes) (Details) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Dec. 31, 2024
Sep. 30, 2024
Jun. 30, 2024
Mar. 31, 2024
Dec. 31, 2023
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Income Tax Disclosure [Abstract]                      
United States                 $ 523 $ 701 $ 407
International                 2,969 2,972 2,276
Earnings before income taxes $ 528 $ 1,043 $ 998 $ 923 $ 1,226 $ 869 $ 899 $ 679 $ 3,492 $ 3,673 $ 2,683
v3.25.0.1
Income Taxes (Schedule of Provision for Income Taxes) (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Current income tax expense (benefit):      
United States federal $ 490 $ 236 $ (76)
United States state and local 90 48 64
International 289 430 279
Total current income tax expense 869 714 267
Deferred income tax expense (benefit):      
United States federal (462) (212) (179)
United States state and local (76) (20) (30)
International 168 26 267
Total deferred income tax expense (benefit) (370) (206) 58
Total income tax expense $ 499 $ 508 $ 325
v3.25.0.1
Income Taxes (Schedule of Difference in Income Tax Effects Comprising Company's Deferred Income Tax Assets and Liabilities) (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Deferred income tax assets:    
Inventories $ 551 $ 521
Other accrued expenses 207 253
Depreciation and amortization 715 918
State income taxes 167 150
Share-based compensation 100 86
Research and development capitalization 408 295
International interest expense carryforwards 52 46
Net operating loss and credit carryforwards 410 385
Outside basis difference related to the anticipated sale of the Spinal Implants business 170 0
Other 310 235
Total deferred income tax assets 3,090 2,889
Less valuation allowances (228) (223)
Net deferred income tax assets 2,862 2,666
Deferred income tax liabilities:    
Depreciation and amortization (1,141) (1,012)
Undistributed earnings (61) (47)
Total deferred income tax liabilities (1,202) (1,059)
Net deferred income tax assets 1,660 1,607
Noncurrent deferred income tax assets 1,742 1,670
Noncurrent liabilities—Other liabilities $ (82) $ (63)
v3.25.0.1
Income Taxes (Schedule of Unresolved Income Tax Positions) (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Unrecognized Tax Benefits [Roll Forward]    
Beginning uncertain tax positions $ 371 $ 286
Increases related to current year income tax positions 18 102
Increases related to prior year income tax positions 0 10
Decreases related to prior year income tax positions (4) (33)
Settlements of income tax audits (21) (1)
Statute of limitations expirations and other (3) 0
Foreign currency translation (12)  
Foreign currency translation   (7)
Ending uncertain tax positions $ 349 $ 371
v3.25.0.1
Retirement Plans (Schedule of Defined Contribution Plan Disclosures) (Details) - USD ($)
shares in Millions, $ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Retirement Benefits [Abstract]      
Plan expense $ 376 $ 327 $ 305
Expense funded with Stryker common stock 62 57 41
Stryker common stock held by plan, amount $ 781 $ 649 $ 522
Stryker common stock held by plan, shares 2.2 2.2 2.1
Stryker common stock held by plan, value as a percentage of total plan assets 10.00% 10.00% 10.00%
v3.25.0.1
Retirement Plans (Schedule of Funded Status and Components of the Amounts Recognized in the Consolidated Balance Sheets and in Accumulated Other Comprehensive Gain (Loss), Before the Effect of Income Taxes) (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Components of Net Periodic Pension Cost      
Service cost $ (39) $ (32) $ (56)
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Interest Cost, Statement Of Income Or Comprehensive Income, Extensible List, Not Disclosed Flag Interest cost Interest cost Interest cost
Interest cost $ (21) $ (23) $ (10)
Expected return on plan assets 19 18 15
Amortization of prior service cost and transition amount 1 1 1
Recognized actuarial loss (1) 4 (9)
Net periodic benefit cost (41) (32) (59)
Net actuarial gain (loss) 43 (67) 244
Recognized net actuarial loss 1 (4) 9
Prior service cost and transition amount (1) (1) (1)
Total recognized in OCI 43 (72) 252
Total recognized in net periodic benefit cost and OCI $ 2 $ (104) $ 193
Defined Benefit Plan, Assumptions Used in Calculations [Abstract]      
Discount rate 2.80% 3.30% 1.10%
Expected return on plan assets 4.30% 4.20% 3.10%
Expected return on plan assets 3.00% 3.00% 2.60%
Weighted-average discount rate used to determine projected benefit obligations 2.90% 2.80% 3.30%
Defined Benefit Plan, Information about Plan Assets [Abstract]      
Fair value of plan assets $ 492 $ 485  
Benefit obligations (782) (826) $ (673)
Funded status (290) (341)  
Total 14 (28)  
Accrued Compensation      
Defined Benefit Plan, Information about Plan Assets [Abstract]      
Funded status (3) (3)  
Other noncurrent assets      
Defined Benefit Plan, Information about Plan Assets [Abstract]      
Funded status 48 21  
Other noncurrent liabilities      
Defined Benefit Plan, Information about Plan Assets [Abstract]      
Funded status (335) (359)  
Accumulated Defined Benefit Plans Adjustment, Net Prior Service Attributable to Parent      
Defined Benefit Plan, Information about Plan Assets [Abstract]      
Unrecognized net actuarial gain (loss) 6 (39)  
Unrecognized prior service credit $ 8 $ 11  
v3.25.0.1
Retirement Plans (Schedule of Change in Benefit Obligations (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]      
Beginning projected benefit obligations $ 826 $ 673  
Service cost 39 32 $ 56
Interest cost 21 23 10
Foreign exchange impact (52) 32  
Employee contributions 7 7  
Actuarial (gains) losses (40) 79  
Benefits paid (19) (20)  
Ending projected benefit obligations 782 826 $ 673
Ending accumulated benefit obligations $ 748 $ 790  
v3.25.0.1
Retirement Plans (Change in Plan Assets) (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]    
Beginning fair value of plan assets $ 485 $ 420
Actual return 22 29
Employer contributions 23 23
Employee contributions 7 7
Foreign exchange impact (31) 22
Benefits paid (14) (16)
Ending fair value of plan assets $ 492 $ 485
v3.25.0.1
Retirement Plans (Schedule of Target and Actual Allocation of Plan Assets) (Details)
Dec. 31, 2024
Dec. 31, 2023
Defined Benefit Plan Disclosure [Line Items]    
Target plan asset allocations 100.00%  
Actual plan asset allocations 100.00% 100.00%
Equity securities    
Defined Benefit Plan Disclosure [Line Items]    
Target plan asset allocations 24.00%  
Actual plan asset allocations 28.00% 28.00%
Debt securities    
Defined Benefit Plan Disclosure [Line Items]    
Target plan asset allocations 44.00%  
Actual plan asset allocations 40.00% 37.00%
Other    
Defined Benefit Plan Disclosure [Line Items]    
Target plan asset allocations 32.00%  
Actual plan asset allocations 32.00% 35.00%
v3.25.0.1
Retirement Plans (Schedule of Valuation of the Company's Pension Plan Assets by Pricing Categories) (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets $ 492 $ 485
(Level 1)    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 31 42
(Level 2)    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 404 378
(Level 3)    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 57 65
Cash and cash equivalents    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 17 15
Cash and cash equivalents | (Level 1)    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 17 15
Cash and cash equivalents | (Level 2)    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 0 0
Cash and cash equivalents | (Level 3)    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 0 0
Equity securities    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 133 150
Equity securities | (Level 1)    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 8 20
Equity securities | (Level 2)    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 125 130
Equity securities | (Level 3)    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 0 0
Debt securities    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 205 187
Debt securities | (Level 1)    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 2 2
Debt securities | (Level 2)    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 203 185
Debt securities | (Level 3)    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 0 0
Other    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 137 133
Other | (Level 1)    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 4 5
Other | (Level 2)    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 76 63
Other | (Level 3)    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets $ 57 $ 65
v3.25.0.1
Retirement Plans (Narrative) (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Defined Benefit Plan Disclosure [Line Items]    
Actual return $ 22 $ 29
(Level 3)    
Defined Benefit Plan Disclosure [Line Items]    
Actual return (8)  
Estimated future employer contributions in next fiscal year $ 21  
v3.25.0.1
Retirement Plans (Expected Benefit Payments) (Details)
$ in Millions
Dec. 31, 2024
USD ($)
Retirement Benefits [Abstract]  
2025 $ 24
2026 23
2027 25
2028 26
2029 27
2030-2034 $ 171
v3.25.0.1
Summary of Quarterly Data (Unaudited) (Details) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended 12 Months Ended
Dec. 31, 2024
Sep. 30, 2024
Jun. 30, 2024
Mar. 31, 2024
Dec. 31, 2023
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Quarterly Financial Data [Abstract]                      
Net sales $ 6,436 $ 5,494 $ 5,422 $ 5,243 $ 5,815 $ 4,909 $ 4,996 $ 4,778 $ 22,595 $ 20,498 $ 18,449
Gross profit 4,174 3,517 3,416 3,333 3,703 3,158 3,181 3,016 14,440 13,058 11,578
Earnings before income taxes 528 1,043 998 923 1,226 869 899 679 3,492 3,673 2,683
Net earnings $ 546 $ 834 $ 825 $ 788 $ 1,143 $ 692 $ 738 $ 592 $ 2,993 $ 3,165 $ 2,358
Basic net earnings per share of common stock (in dollars per share) $ 1.43 $ 2.18 $ 2.17 $ 2.07 $ 3.01 $ 1.82 $ 1.95 $ 1.56 $ 7.86 $ 8.34 $ 6.23
Diluted net earnings per share of common stock (in dollars per share) 1.41 2.16 2.14 2.05 2.98 1.80 1.93 1.54 $ 7.76 $ 8.25 $ 6.17
Dividends declared per share of common stock (in dollars per share) $ 0.84 $ 0.80 $ 0.80 $ 0.80 $ 0.80 $ 0.75 $ 0.75 $ 0.75      
v3.25.0.1
Segment and Geographic Data (Sales And Other Financial Information By Business Segment) (Details)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2024
USD ($)
Sep. 30, 2024
USD ($)
Jun. 30, 2024
USD ($)
Mar. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Sep. 30, 2023
USD ($)
Jun. 30, 2023
USD ($)
Mar. 31, 2023
USD ($)
Dec. 31, 2024
USD ($)
segment
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Segment Reporting [Abstract]                      
Number of reportable segments | segment                 2    
Segment Reporting Information [Line Items]                      
Number of reportable segments | segment                 2    
Net sales $ 6,436,000 $ 5,494,000 $ 5,422,000 $ 5,243,000 $ 5,815,000 $ 4,909,000 $ 4,996,000 $ 4,778,000 $ 22,595,000 $ 20,498,000 $ 18,449,000
Cost of sales                 8,155,000 7,440,000 6,871,000
Research, development and engineering expenses                 1,466,000 1,388,000 1,454,000
Selling, general and administrative expenses                 7,685,000 7,111,000 6,386,000
Depreciation and amortization                 1,426,000 1,341,000 1,278,000
Amortization of intangible assets                 (623,000) (635,000) (627,000)
Segment net earnings (loss)                 3,689,000 3,888,000 2,841,000
Sale of inventory stepped up to fair value at acquisition                 (46,000) 0 (12,000)
Goodwill and other impairments                 (977,000) (36,000) (270,000)
Net earnings $ 546,000 $ 834,000 $ 825,000 $ 788,000 $ 1,143,000 $ 692,000 $ 738,000 $ 592,000 2,993,000 3,165,000 2,358,000
MedSurg and Neurotechnology                      
Segment Reporting Information [Line Items]                      
Net sales                 13,518,000 12,163,000 10,893,000
Operating Segments                      
Segment Reporting Information [Line Items]                      
Net sales                 22,595,000 20,498,000 18,449,000
Cost of sales                 7,720,000 7,130,000 6,557,000
Research, development and engineering expenses                 1,324,000 1,210,000 1,159,000
Selling, general and administrative expenses                 6,314,000 5,856,000 5,172,000
Depreciation and amortization                 641,000 567,000 528,000
Amortization of intangible assets                 (623,000) (635,000) (627,000)
Segment net earnings (loss)                 6,595,000 5,735,000 5,033,000
Operating Segments | MedSurg and Neurotechnology                      
Segment Reporting Information [Line Items]                      
Net sales                 13,518,000 12,163,000 10,893,000
Cost of sales                 5,320,000 4,876,000 4,637,000
Research, development and engineering expenses                 784,000 702,000 682,000
Selling, general and administrative expenses                 3,203,000 2,934,000 2,564,000
Depreciation and amortization                 208,000 181,000 178,000
Segment net earnings (loss)                 4,004,000 3,470,000 2,831,000
Operating Segments | Orthopaedics                      
Segment Reporting Information [Line Items]                      
Net sales                 9,077,000 8,335,000 7,556,000
Cost of sales                 2,400,000 2,254,000 1,920,000
Research, development and engineering expenses                 540,000 508,000 477,000
Selling, general and administrative expenses                 3,111,000 2,922,000 2,608,000
Depreciation and amortization                 433,000 386,000 350,000
Segment net earnings (loss)                 2,591,000 2,265,000 2,202,000
Corporate and Other                      
Segment Reporting Information [Line Items]                      
Depreciation and amortization                 162,000 139,000 123,000
Segment operating income                 (880,000) (780,000) (649,000)
Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment                      
Segment Reporting Information [Line Items]                      
Sale of inventory stepped up to fair value at acquisition                 (46,000) 0 0
Acquisition and integration-related charges                 (108,000) (20,000) (138,000)
Structural optimization and other special charges                 (138,000) (170,000) (295,000)
Medical device regulation                 (58,000) (96,000) (140,000)
Recall-related matters                 (40,000) (18,000) 15,000
Regulatory and legal matters                 (36,000) (92,000) (76,000)
Net earnings                 $ 3,689,000 $ 3,888,000 $ 2,841,000
v3.25.0.1
Segment and Geographic Data (Segment Information) (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Segment Reporting Information [Line Items]      
Assets $ 42,971 $ 39,912  
Capital Expenditures During Period 755 575 $ 588
Operating Segments      
Segment Reporting Information [Line Items]      
Assets 41,622 38,827  
Capital Expenditures During Period 506 362 348
Operating Segments | MedSurg and Neurotechnology      
Segment Reporting Information [Line Items]      
Assets 23,115 20,804  
Capital Expenditures During Period 276 183 175
Operating Segments | Orthopaedics      
Segment Reporting Information [Line Items]      
Assets 18,507 18,023  
Capital Expenditures During Period 230 179 173
Corporate and Other      
Segment Reporting Information [Line Items]      
Assets 1,349 1,085  
Capital Expenditures During Period $ 249 $ 213 $ 240
v3.25.0.1
Segment and Geographic Data (Geographic Information on Net Sales and Long-Lived Assets) (Details) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Dec. 31, 2024
Sep. 30, 2024
Jun. 30, 2024
Mar. 31, 2024
Dec. 31, 2023
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Segment Reporting Information [Line Items]                      
Net sales $ 6,436 $ 5,494 $ 5,422 $ 5,243 $ 5,815 $ 4,909 $ 4,996 $ 4,778 $ 22,595 $ 20,498 $ 18,449
Net Property, Plant & Equipment 3,448       3,215       3,448 3,215  
United States                      
Segment Reporting Information [Line Items]                      
Net sales                 16,943 15,257 13,638
Net Property, Plant & Equipment 1,997       1,874       1,997 1,874  
Europe, Middle East, Africa                      
Segment Reporting Information [Line Items]                      
Net sales                 2,897 2,618 2,348
Net Property, Plant & Equipment 1,260       1,151       1,260 1,151  
Asia Pacific                      
Segment Reporting Information [Line Items]                      
Net sales                 2,020 1,946 1,885
Net Property, Plant & Equipment 75       77       75 77  
Other foreign countries                      
Segment Reporting Information [Line Items]                      
Net sales                 735 677 $ 578
Net Property, Plant & Equipment $ 116       $ 113       $ 116 $ 113  
v3.25.0.1
Asset Impairments (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Property, Plant and Equipment [Line Items]      
Goodwill and other impairments $ 977 $ 36 $ 270
Long-Lived Assets and Intangible Assets      
Property, Plant and Equipment [Line Items]      
Goodwill and other impairments $ 159 $ 36 $ 54
v3.25.0.1
Assets Held for Sale (Details) - Disposal Group, Held-for-Sale, Not Discontinued Operations - Spinal Implants
$ in Millions
 3 Months Ended
Dec. 31, 2024
USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]  
Loss on disposition of assets $ 362
Increase to fair value 84
Decrease to fair value 218
Disposal Group, Including Discontinued Operation, Assets [Abstract]  
Accounts receivable, net 62
Total inventories 183
Prepaid expenses and other current assets 10
Property, plant and equipment, net 51
Other intangibles, net 326
Noncurrent deferred income tax assets 9
Other noncurrent assets 171
Valuation allowance (362)
Total assets held for sale 450
Disposal Group, Including Discontinued Operation, Liabilities, Current [Abstract]  
Accounts payable 28
Accrued compensation 26
Accrued expenses and other liabilities 29
Other noncurrent liabilities 21
Total liabilities held for sale $ 104
v3.25.0.1
Subsequent Events (Details) - Subsequent Event - USD ($)
$ / shares in Units, $ in Millions
 1 Months Ended
Jan. 31, 2025
Feb. 12, 2025
Senior Unsecured Notes, 4.550% Due February 10, 2027 | Senior Notes    
Subsequent Event [Line Items]    
Stated interest rate   4.55%
Debt face amount   $ 500
Senior Unsecured Notes 4.700% Due February 10, 2028 | Senior Notes    
Subsequent Event [Line Items]    
Stated interest rate   4.70%
Debt face amount   $ 700
Senior Unsecured Notes 4.850% Due February 10, 2030 | Senior Notes    
Subsequent Event [Line Items]    
Stated interest rate   4.85%
Debt face amount   $ 800
Senior Unsecured Notes 5.200% Due February 28, 2035 | Senior Notes    
Subsequent Event [Line Items]    
Stated interest rate   5.20%
Debt face amount   $ 1,000
Inari    
Subsequent Event [Line Items]    
Business combination, price of acquisition, expected $ 4,900  
Common Stock | Inari    
Subsequent Event [Line Items]    
Business acquisition, share price (in dollars per share) $ 80  
v3.25.0.1
Schedule II Valuation and Qualifying Accounts (Details) - SEC Schedule, 12-09, Allowance, Notes Receivable - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]      
Balance at Beginning of Period $ 182 $ 154 $ 167
Charged to Costs & Expenses 69 69 41
Uncollectible Amounts Written Off, Net of Recoveries 36 40 52
Effect of Changes in Foreign Currency Exchange Rates 2 1 2
Balance at End of Period $ 213 $ 182 $ 154